Systematic Optimization of Bone Pharmaceuticals to Maximize Therapeutic Response in Conditions of Low Bone Mass by Dillstrom, Diana
Systematic Optimization of Bone Pharmaceuticals to Maximize Therapeutic Response in Conditions 
of Low Bone Mass 
 
by 
 
Diana Dillstrom 
A dissertation submitted in partial fulfillment 
 of the requirements for the degree of  
Doctor of Philosophy  
(Biomedical Engineering)  
in the University of Michigan 
2018 
Doctoral Committee: 
 
Associate Professor Kenneth M. Kozloff, Chair  
Associate Professor Michelle S. Caird 
Professor David H. Kohn  
Professor Ernestina Schipani  
 
 
  
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Diana Dillstrom 
dolvera@umich.edu 
ORCID iD:  0000-0002-1585-6616 
© Diana Dillstrom 2018 
All rights reserved 
 
 
  
  
 
 
 ii 
Dedication 
 
Para mi esposo, gracias por darme las alas para vivir una vida sin limites.
 iii 
Acknowledgements 
 
I would like to take this opportunity to acknowledge and thank those who have had an 
undeniable, positive impact on my professional development, and to whom I wish to express my 
sincerest gratitude for sacrificing their time and efforts to encourage, teach, and challenge me. 
First and foremost, I would like to thank my advisor, Dr. Ken Kozloff, for his professional 
guidance. Apart from providing an environment with the freedom to pursue research topics of my 
interest, he continuously encouraged me to keep thinking of the “big picture. In addition, I express 
my appreciation to my thesis committee, Professors Michelle Caird, David Kohn and Ernestina 
Schipani, for graciously donating their time and expertise to the execution of this dissertation. 
Their insightful comments, constructive feedback, and thoughtful questions were valued greatly.  
To members of the Kozloff lab, thank you for your help and support throughout these years, 
especially Rachel Stolzenfeld and Emily Fisher, whom I had the pleasure to mentor. Thank you 
for keeping up with my ambitious deadlines, your interest in the importance of these studies and 
for being significant contributors in the completion of this work. In addition, Rachel Surowiec and 
Ted Ahn, thank you for always being there personally and professionally. I will definitely miss 
our talks and our annual “Tour de Fries”, but I hope our paths will cross on the slopes! 
I warmly thank all members of the Orthopaedic Research Laboratories, especially Bonnie 
Nolan and Carol Whitinger; you two are truly irreplaceable and deserve significant credit for the 
completion of this work. Bonnie, thank you for your personal guidance, always being there for me. 
My experience throughout this journey would definitely not be the same without you. Carol, thank 
you for introducing me to croquet, for being there for me, and for keeping up with my ambitious 
 iv 
goals. Karl Jepsen, I am extremely grateful for your professional and financial support. Erin 
Bigelow, thank you for walking me through basic fuchsin protocols and for bringing Hamilton 
puns into my life. Rob Goulet, thank you for keeping my computer alive and for saving me some 
pizza when I couldn’t attend seminars. To members of Bone Crushers trivia, thank you for bringing 
sanity and joy into my life. To Natalie, Sharon and Peggy, thank you for always answering my 
reimbursement questions and for all the magic you provide in taking care of the administrative 
side of things. 
To my friends I have gained through this journey and to those who continue to be part of 
my life, I am grateful for our camaraderie and the joy we have shared. Thank you for always 
cheering me on and for encouraging me from all over the world.  
Most importantly, I am thankful for the unconditional love and support I have received 
from my family throughout this process. My parents, Maria and Primitivo, have always 
encouraged me to dream big and without the opportunities they provided me with I wouldn’t be 
here today. My siblings, Gaston and Anibal, thank you for always motivating me and always being 
there for me since we were little. To my in-laws, thank you for your constant love and support 
throughout this journey. Lastly, I feel incredibly lucky to have had my husband Tyler throughout 
this journey. Whether near or far, you have always made my success a priority and have been my 
number one fan since the beginning. Thank you for being my solid anchor and for your unwavering 
patience; this accomplishment would not have been possible without you. 
  
 v 
 
Table of Contents 
Dedication ...................................................................................................................................... ii 
Acknowledgements ...................................................................................................................... iii 
Abstract ......................................................................................................................................... ix 
Chapter 1 Introduction................................................................................................................. 1 
Osteogenesis Imperfecta ..................................................................................................... 1 
Therapeutics for Osteogenesis Imperfecta .......................................................................... 3 
Thesis Motivation ............................................................................................................... 5 
Thesis Overview ................................................................................................................. 7 
Chapter 2: Bisphosphonate Treatment Intervention during Pregnancy and 
Lactation Leads to Temporal Inhibition of Lactation-Induced Bone Loss on the 
Maternal Skeleton ................................................................................................... 7 
Chapter 3: Low Dose of Bisphosphonate Enhances Sclerostin Antibody-Induced 
Trabecular Bone Mass Gains in Brtl/+ Osteogenesis Imperfecta Mouse Model . 11 
Thesis Contributions ......................................................................................................... 13 
Chapter 2 Bisphosphonate Treatment Intervention during Pregnancy and Lactation Leads 
to Temporal Inhibition of Lactation-Induced Bone Loss on the Maternal Skeleton ........... 15 
Introduction ....................................................................................................................... 15 
Materials and Methods ...................................................................................................... 18 
Experimental design.............................................................................................. 18 
Non-therapeutic fluorescent bisphosphonate probe .............................................. 19 
FRFP Imaging ....................................................................................................... 19 
Micro-computed tomography (μCT) .................................................................... 20 
Backscatter scanning electron microscopy ........................................................... 21 
Biomechanical testing ........................................................................................... 21 
Tartrate‐resistant acid phosphatase staining ......................................................... 22 
Statistics ................................................................................................................ 23 
 vi 
Results ............................................................................................................................... 24 
Maternal and neonatal body weight are not affected with pamidronate treatment 24 
Pamidronate effects on pregnacy and lactation-induced bone changes are highly 
dependent on time of treatment............................................................................. 24 
PAM-induced preservation of trabecular and cortical bone increases stiffness but 
not strength during pregnancy and lactation ......................................................... 26 
BPs cross the placenta and diffuse into the breast milk ........................................ 27 
Neonates at birth and weaning did not show skeletal adverse effects from 
maternal pamidronate exposure ............................................................................ 27 
Pamidronate increases maternal osteoclast number and surface but has no effect 
on neonates exposed to BPs during early stage of skeletal formation and lactation
............................................................................................................................... 28 
Pamidronate did not further increase osteocyte lacunar area during pregnancy .. 28 
Discussion ......................................................................................................................... 29 
Figures............................................................................................................................... 39 
Chapter 3 Low Dose of Bisphosphonate Enhances Sclerostin Antibody-Induced Trabecular 
Bone Mass Gains in Brtl/+ Osteogenesis Imperfecta Mouse Model ...................................... 47 
Introduction ....................................................................................................................... 47 
Materials and Methods ...................................................................................................... 49 
Animals ................................................................................................................. 49 
Micro–computed tomography ............................................................................... 50 
Bone histomorphometry........................................................................................ 52 
Biomechanical testing ........................................................................................... 52 
Statistics ................................................................................................................ 53 
Results ............................................................................................................................... 53 
PAM and SclAb contribute distinct gains in distal femoral trabecular number and 
thickness following a single cycle of combination therapy .................................. 53 
Multiple cycles help stabilize bone mass gains from combination treatment ...... 54 
Multiple treatments of PAM and SclAb significantly slows the turnover of 
primary spongiosa ................................................................................................. 56 
Multiple cycles of combination therapy induce synergistic gains in vertebral 
trabecular bone mass ............................................................................................. 56 
Substantial preservation of Tb.N and increased Tb.Th in vertebral body ............ 58 
PAM intervention does not interfere with SclAb ability to improve femoral 
rigidity ................................................................................................................... 58 
PAM and SclAb synergistically improve Brtl/+ vertebral stiffness over 
80monotherapy effects .......................................................................................... 59 
 vii 
Discussion ......................................................................................................................... 60 
Figures............................................................................................................................... 66 
Tables ................................................................................................................................ 75 
Chapter 4 Conclusions ................................................................................................................ 81 
Bisphosphonate Treatment Intervention during Pregnancy and Lactation Leads to 
Temporal Inhibition of Lactation-Induced Bone Loss on the Maternal Skeleton ............ 81 
Limitations ............................................................................................................ 82 
Future Directions .................................................................................................. 85 
Low Dose of Bisphosphonate Enhances Sclerostin Antibody-Induced Trabecular Bone 
Mass Gains in Brtl/+ Osteogenesis Imperfecta Mouse Model ......................................... 87 
Limitations ............................................................................................................ 88 
Future Directions .................................................................................................. 89 
Bibliography ................................................................................................................................ 91
 viii 
List of Tables 
 
Table 3.1: Trabecular response at the femur following single cycle of combination therapy. .... 75 
Table 3.2: Isolated effects proximal and distal to site of concurrent drug administration. .......... 76 
Table 3.3: Trabecular response at the femur following two cycles of combination therapy ....... 77 
Table 3.4: Trabecular response in the vertebra following single cycle of combination therapy. 78 
Table 3.5: Effects on femoral mechanical and cortical properties from a single and concurrent 
cycles of combination therapy. ..................................................................................................... 79 
Table 3.6: Effects on vertebral mechanical and cortical properties from a single and concurrent 
cycles of combination therapy. ..................................................................................................... 80 
 ix 
List of Figures 
 
Figure 2.1: Assessing PAM effects at different stages of pregnancy and lactation in the maternal 
skeleton and its effects on offspring bone development from PAM exposure. ............................ 39 
Figure 2.2: Maternal and neonatal body weight are not affected with pamidronate treatment. .. 40 
Figure 2.3: Pamidronate effects on pregnacy and lactation-induced bone changes are highly 
dependent on time of treatment..................................................................................................... 41 
Figure 2.4: PAM-induced preservation of trabecular and cortical bone increases stiffness but not 
strength during pregnancy and lactation. ...................................................................................... 42 
Figure 2.5: BPs cross the placenta and diffuse into the breast milk. ........................................... 43 
Figure 2.6: Neonates at birth and weaning did not show skeletal adverse effects from maternal 
pamidronate exposure. .................................................................................................................. 44 
Figure 2.7: Pamidronate increases maternal osteoclast number and surface but has no effect on 
neonates exposed to BPs during early stage of skeletal formation and lactation. ........................ 45 
Figure 2.8: Pamidronate did not further increase osteocyte lacunar area during pregnancy. ...... 46 
Figure 3.1: Schematic of short and long-term treatment timelines and ROI placement. ............ 66 
Figure 3.2: Trabecular response at the femur following single cycle of combination therapy. .. 67 
Figure 3.3: Isolated effects proximal and distal to site of concurrent drug administration. ........ 68 
Figure 3.4: Trabecular response at the femur following two cycles of combination therapy. .... 69 
Figure 3.5: Metaphyseal bone formation activity mapped with calcein and alizarin following a 
single and concurrent cycles of combination therapy. .................................................................. 70 
 x 
Figure 3.6: Trabecular response in the vertebra following single cycle of combination therapy.71 
Figure 3.7: Vertebral bone formation activity mapped with calcein and alizarin following a 
single and concurrent cycles of combination therapy. .................................................................. 72 
Figure 3.8: Effects on femoral mechanical and cortical properties from a single and concurrent 
cycles of combination therapy. ..................................................................................................... 73 
Figure 3.9: Effects on vertebral mechanical and cortical properties from a single and concurrent 
cycles of combination therapy. ..................................................................................................... 74 
 xi 
 
Abstract 
Osteogenesis imperfecta (OI) is a genetic disorder caused by collagen-related mutations 
which leads to increased bone fragility and low bone mass. Although the past decade has been 
marked by numerous advances in therapies that aim to stabilize the onset of metabolic bone 
disease, current treatment strategies leave room for substantial improvements. The studies that will 
be presented in this thesis focus on designing systematic treatments for two challenging clinical 
scenarios that require novel approaches. All studies have been approached in the context of OI 
using the Brtl/+ mouse model.  
While the maternal skeleton goes through significant bone loss during pregnancy and 
lactation, this period of skeletal vulnerability can exacerbate an underlying metabolic bone 
condition like OI. In view of increasing use of bisphosphonates (BP) in premenopausal women to 
treat OI, the potential risks from long-term exposure on both maternal and neonatal skeleton during 
pregnancy and lactation remain inconclusive. When we assessed the maternal skeletal changes 
during pregnancy and lactation in Brtl/+ dams, pregnancy led to maternal trabecular gains in 
vertebral bone mass, while lactation induced maternal cortical and trabecular bone loss in both 
vertebra and femur. When BPs were administered prior to conception, bone mass gains due to 
pregnancy were amplified and lactation-induced bone loss was prevented. However, this protective 
effect was more modest with BP intervention during pregnancy, and ceased to exist in the late 
stages of lactation. Despite preventing lactation-induced maternal bone loss, no negative skeletal 
effects of BPs on offspring were observed. These findings indicate that during this period of 
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significant imbalance between bone resorption and formation, BPs can help reduce the risk of 
maternal bone fragility in OI by inhibiting lactation-induced bone resorption without affecting 
bone development in their offspring.  
The second half of this thesis explores clinical cases with a critically depleted bone 
structure, such as severe OI. These cases pose a challenge to current antiresorptive and anabolic 
therapeutics since their response mechanisms target different abnormalities in the bone remodeling 
cycle. In this study, rapidly growing Brtl/+ mice were treated with a combination of pamidronate 
(PAM) and an anabolic (SclAb) in order to attain superior bone mass and strength effects compared 
to monotherapy. Results from this study showed that following one cycle of combination therapy, 
a single dose of PAM in combination with SclAb led to a cumulative effect on bone mass, but each 
through independent means. PAM retention mechanism led to an increase in trabecular number as 
the dosage increased while no additional gains were observed with SclAb. Conversely, while PAM 
showed no significant effect on trabecular thickness, SclAb induced a consistent trabecular 
thickening across all BP dosages. Chronic effects of concurrent administration of BP and SclAb 
revealed that accumulating cycles conferred synergistic gains in trabecular mass and vertebral 
stiffness, suggesting a distinct advantage of both therapies combined.  
Given the lack of knowledge regarding the effects of BPs during reproductive periods and 
lack of treatment options for patients with severe OI, this thesis provides valuable insight that can 
help develop patient-specific treatment plans. By understanding the changes in bone metabolism 
of the clinical conditions we are trying to resolve, and by combining this knowledge with our 
understanding of the targeted pathways of available pharmaceuticals, we can strategically and 
systematically optimize bone therapeutics so that the best clinical outcome can be achieved. 
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Chapter 1 Introduction 
 
Bone is a metabolically active tissue that undergoes continuous change through the process of bone 
resorption and bone formation [1]. This lifelong remodeling process, guided by osteoblasts and 
osteoclasts, is essential for maintaining optimal bone strength and mineral homeostasis [2]. 
Normally, remodeling is coupled such that the level of resorption is equal to the level of formation 
and bone density remains constant. In disorders of bone fragility, these functions become impaired 
and bone begins to deteriorate in composition, structure and functionality. The most prevalent 
example of such disorders is osteoporosis, which is marked by a decrease in bone mineral density 
(BMD) and strength. However, disorders of bone fragility may arise from a variety of different 
causes, with differing pathologies contributing to fragility.  Such is the case of the rare metabolic 
bone disorder known as osteogenesis imperfecta which results from inherited genetic mutations 
and results in variable skeletal fragility over time.  
 
Osteogenesis Imperfecta 
Osteogenesis imperfecta (OI), or brittle bone disease, is a genetic metabolic bone disorder caused 
by collagen-related mutations with an estimated prevalence of approximately 1 per 20,000 births 
[3].  Although symptoms vary widely among patients, the skeletal phenotype most commonly 
associated with OI is low bone mass, altered bone quality, and imbalanced bone remodeling [4]. 
As a result, bone fragility is a cardinal symptom in OI with its severity ranging from mild to severe. 
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Clinical observations have shown that the annual fracture rate in OI patients is most prominent 
during childhood in both males and females [5]. Though the symptoms vary over time, the 
condition persists throughout life. Dominant forms of OI encompass about 90% of clinical cases 
and are characterized by mutations in one of the two genes, COL1A1 and COL1A2, encoding the 
α1 and α2 chains of type I collagen [6]. The clinical severity from these mutations ranges from 
mild to perinatal lethal and currently more than 2500 distinct variants in the COL1A1 and COL1A2 
genes have been identified [7]. For instance, individuals with a mild clinical diagnosis of OI, such 
as type I, have been shown to have one null allele from a premature translation termination codon 
which consequently reduces secretion of normal procollagen by 50%  [8].  In more severe cases, 
the mutation is most often caused from an amino acid substitution for glycine, while few non-
glycine substitutions in the triple helical domain have been reported [9-13]. In addition to these 
point mutations, splice site mutations can also result in the production of abnormal and impaired 
collagen type I molecules [6]. During collagen synthesis, two α1 chains and one α2 chain assemble 
into a triple helix structure where glycine, the smallest amino acid, is required at every third 
position of the peptide chain to produce a tightly packed and stabilized helical structure [14]. 
Therefore, point mutations of even one glycine lead to delayed folding of the triple helix that can 
cause asymmetric post-translational overmodification of the chains. On the other hand, splice site 
alterations can lead to in-frame sequence alterations or cause exon skipping [6]. The remaining 
clinical cases are recessive forms of OI caused by deficiency or mutations of genes encoding 
proteins required for collagen post-translational modifications, folding or secretion of type I 
collagen [4]. However, to date, it remains unclear how mutation type, location, and gene contribute 
directly to OI bone fragility. 
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In an effort to describe the range of phenotypic severity in OI, Sillence proposed a numerical 
classification scheme based on clinical and radiographic features [15].  Type I is a non-deforming 
form of OI that in spite of normal height may be expressed through blue-tinted sclera and a higher 
than normal fracture risk. More severe cases include perinatal lethal type II, progressive deforming 
type III and moderate deforming type IV. More recently, molecular genetics have identified more 
types of OI (up to type XVIII) [16], but types I-IV encompass the bulk of OI cases. In this thesis 
we will be focusing on OI type VI.   
 
Therapeutics for Osteogenesis Imperfecta 
Currently there is no cure for OI, but treatments have been designed with the goal to decrease pain, 
prevent fractures and improve mobility. Current treatment approaches for managing OI are 
comprised of physical therapy, rehabilitation, orthopaedic surgery and medical-pharmacological 
management. Although surgical interventions aim to prevent and correct long-bone deformities 
that impair function, due to the bone’s poor quality, multiple surgeries are required for their success 
which may lead to further complications and increase time spent in the hospital. While these types 
of surgeries remain the mainstay of treatment in children with OI, advances in the pharmacological 
management of OI have focused on stabilizing the underlying metabolic disease by addressing its 
low bone mass characteristics[17].  
At the cellular level, patients with OI have increased osteoclastic bone resorption, thus 
bisphosphonates (BP) are considered the standard care for treating OI due to their ability to inhibit 
osteoclast activity[18]. BPs have been known to chemists since the middle of 19th century, when 
they were mainly used as corrosion inhibitors or as agents in textile, fertilizer, and oil industries. 
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However it wasn’t until observations of BPs ability to inhibit the dissolution of hydroxyapatite 
crystals that led to their use as therapeutic interventions for metabolic bone diseases [19]. Various 
OI clinical studies have shown BPs effectiveness in decreasing bone turnover and increasing bone 
mineral density [20-26]. However, it is important to note that BPs do not actively build bone tissue. 
Rather than directly addressing osteoblasts that harbor the OI-causing collagen mutation, their 
effect is strictly on inhibiting bone resorption. As a result, BPs effect on OI fracture prevention 
remains inconclusive. Studies using an OI mouse model with a phenotype of spontaneous fractures 
showed that alendronate treatment increased bone volume and decreased fracture incidence [27, 
28]. However in another OI animal study using antiresorptive denosumab, an antibody against 
RANKL, a significant increase in bone mineral density was observed but fracture incidence was 
not reduced [29]. Similar observations have been shown in clinical studies where fracture 
incidence was reduced in the vertebral body but not in long-bones [21, 24, 30-33].  
Recently, therapies with bone-anabolic capabilities have attracted general interest, especially since 
genetic defects underlying OI primarily affect collagen type I which is synthesized by osteoblasts. 
A study using growth hormone therapy showed the drug’s effectiveness in increasing linear bone 
growth, but its effects were not seen in all pediatric patients [34]. Significant increase in bone 
density with teriparatide, a recombinant human form of parathyroid hormone, was observed in 
adults with mild OI [35]. However, currently the FDA has not approved its used in children since 
preclinical rat studies showed the potential risk of osteosarcoma induction in addition to increased 
bone mass [36]. Sclerostin is an antagonist to the Wnt signaling pathway which has increasingly 
received attention as a potential target for anabolic treatment of metabolic bone diseases. Sclerostin 
is encoded by the SOST gene and is primarily expressed in mature osteocytes [37]. The role of 
sclerostin in bone development was identified when studies showed that bone overgrowth 
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disorders like sclerosteosis and van Buchem disease were caused by inactivating mutations in the 
SOST gene [38, 39]. In both animal models and case studies, loss of sclerostin activity has shown 
an increase in osteoblast activity and an upregulation in bone formation markers which 
consequently induces a significant increase in bone mass [40, 41]. Conversely, transgenic mice 
overexpressing the SOST gene exhibited osteopenia due to inhibited osteogenic differentiation and 
stimulated osteoblast apoptosis [42, 43]. As a result, monoclonal inhibiting antibodies that mimic 
the loss of sclerostin/SOST were developed and initially tested in animal models of osteoporosis. 
These preclinical studies confirmed the anabolic efficacy of sclerostin antibody (SclAb) where a 
significant increase in bone mass and strength was observed [44-46]. Due to sclerostin’s potency 
in inhibiting bone formation in cases of osteoporosis, its application in OI has recently been 
explored. Our group and others have invested considerable effort into establishing the anabolic 
efficacy of SclAb in a variety of animal models with an OI phenotype [47-53]. 
 
Thesis Motivation 
Although the past decade has been marked by numerous advances in therapies that aim to stabilize 
the onset of metabolic bone disease, current treatment strategies leave room for substantial 
improvements. In this thesis, we have focused on two challenging clinical scenarios that require 
novel therapeutic approaches: 
1) Pregnancy and lactation-associated osteoporosis (PLO) and pregnancy associated osteoporosis 
(PAO) are rare form of osteoporosis characterized by the occurrence of fracture during late 
pregnancy or during the postpartum period [54, 55]. While the maternal skeleton goes through 
significant bone loss during pregnancy and lactation, this period of skeletal vulnerability has 
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not been clearly associated with increased maternal fracture risk. However, these physiological 
conditions can exacerbate an underlying metabolic bone condition like OI [56, 57]. In view of 
the increasing use of BPs in premenopausal women to treat OI, the potential risks from long-
term exposure on both maternal and neonatal skeleton during pregnancy and lactation remain 
inconclusive. Even if administration has been ceased during pregnancy, due to their long half-
life, there remains a risk that embedded BPs can be released into the bloodstream and 
consequently cross the placenta or diffuse into the breast milk during these periods of high 
calcium demand. Additionally, since BPs have been known to suppress osteoclastic resorption, 
their effect on pregnancy and lactation-induced bone loss can lead to changes in calcium 
homeostasis and indirectly affect fetal and neonatal bone development. We hypothesize that 
BP intervention during pregnancy and lactation will induce a temporal effect on trabecular and 
cortical maternal bone structure that is representative of the changes in calcium metabolism 
that are occurring during these reproductive periods. Identifying this therapeutic window can 
help minimize this period of maternal skeletal vulnerability that can be exacerbated in women 
with an underlying disease like OI.  
2) Clinical cases with a critically depleted bone structure, such as severe osteoporosis and severe 
OI, pose a challenge to current antiresorptive and anabolic therapeutics since their response 
mechanism target different abnormalities in the bone remodeling cycle. Although both 
antiresorptive and anabolic agents have clinically shown significant improvements in bone 
mineral density [25, 58, 59], they have both failed to achieve an adequate response in cases 
where trabecular structure is limited due to excessive bone turnover [60-63]. Since 
antiresorptive agents preserve trabecular number by targeting osteoclasts and anabolic agents 
induce trabecular thickening by targeting pathways of osteoblast-mediated bone formation, 
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combining both therapeutics may provide distinct advantages over either treatment alone. We 
hypothesize that a minimal BP dose, that would otherwise be too weak to preserve long-term 
bone mass, will preserve primary trabecular architecture and serve as a substrate for additional 
bone formation with subsequent SclAb treatment. 
 
Thesis Overview 
The studies that will be presented in this thesis have been approached in the context of OI using 
the Brtl/+ mouse model. This knock-in model for moderately severe Type IV OI is heterozygous 
for a glycine to cysteine (G349C) substitution in one COL1A1 allele, reproducing features 
observed in a clinical phenotype such as low bone mass and skeletal fragility [64]. The Brtl/+ 
mouse have been proven suitable for studying the effects of therapeutics in OI since it recapitulates 
the clinically observed phenotype [65-67]. 
Chapter 2: Bisphosphonate Treatment Intervention during Pregnancy and Lactation Leads to 
Temporal Inhibition of Lactation-Induced Bone Loss on the Maternal Skeleton  
Chapter 2 addresses the significant loss in maternal bone structure that may exacerbate metabolic 
bone disorders like OI and its effects when treated with BPs. While pregnancy and lactation-
induced bone loss is not clearly associated with increased maternal fracture risk, these physiologic 
conditions still pose several potential challenges in women with OI. It is not recommended to use 
pharmaceuticals during pregnancy and lactation, however, OI patients are more likely to be treated 
with BPs prior to conception than any other population. In fact, case studies have reported 
instances where BP therapy is stopped as soon as pregnancy is confirmed in women with OI [68]. 
Upon administration, BPs initially bind to hydroxyapatite crystals within the bone matrix and 
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become sequestered in the bone matrix [18]. Activation of BPs occurs when they are released from 
the bone surface by osteoclasts, which subsequently reduces bone turnover through inhibition of 
osteoclast activity [69]. Because BP can remain embedded within the bone matrix until they are 
taken up by osteoclasts, there is rising concern that premenopausal women placed on BP early in 
life might encounter drug release during pregnancy or lactation, resulting in fetal or neonatal 
exposure with unknown consequences. 
During pregnancy, the placenta plays a crucial role in nourishing the fetus by enabling the transfer 
of oxygen, carbon dioxide and essential vitamins and minerals from the maternal blood supply. 
For a long time, the general opinion was that the placenta served as a barrier that protected the 
fetus from harmful agents during pregnancy. However, it wasn’t until the thalidomide tragedy, 
when numerous report of malformations in babies brought about awareness of the imperfect state 
of the placenta as a barrier to drug transfer [70]. Initially, studies focused on noticeable effects like 
congenital malformations and developmental disorders, but later it became clear that manifestation 
of teratogenicity also included infertility, spontaneous abortions, intrauterine death, premature 
birth, low birth weight, and organ failure; since exposure to certain drugs during pregnancy may 
alter the function of the placenta or interfere with the environment within the uterus [71, 72]. 
Similarly, during lactation, the physiologic process of breastfeeding plays an essential nutritional 
and protective role during infant development [73]. However, since it is well established that 
anything taken by the nursing mother may diffuse into the breast milk [74-77] and therefore 
become bioavailable to the infant, it has also become imperative to establish the potential risks in 
neonatal development following drug exposure.  
Although the majority of unbound medication is transported across the placenta by passive 
diffusion, several other factors (protein binding, pH difference or lipid solubility) can affect their 
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ability to cross the placenta [78]. Pharmaceuticals with a low molecular weight (< 500 g/mol) 
diffuse freely across the placenta, those with moderate molecular weights (500 – 1000 g/mol) cross 
the placenta less easily, while those with a high molecular weight (> 1000 g/mol) do not cross the 
placenta [78]. As a result, several studies have shown that BP, with a molecular weight of between 
235.07 g/mol and 249.096 g/mol, crosses the placenta in various animal models [79-82]. However, 
these studies have failed to agree on the drug’s effects on the developing fetus after in utero 
exposure. Moreover, human reports concerning women exposed to BPs before conception or 
during pregnancy did not demonstrate serious adverse effects to fetuses [83-87].  
The transfer of drugs into the breast milk shares some of the same principles as crossing the 
placenta, mostly through passive diffusion. Studies have shown that medication may diffuse into 
the milk and back into the bloodstream based on the amount of drug concentration in maternal 
serum [88]. Similar to crossing the placenta, molecular weight can predict a medication's 
likelihood to cross into breast milk. Medications with small molecular weights (< 200 Da) are 
more likely to cross than those with a larger molecular weight. However, many other properties 
may also affect their diffusivity such as bio-availability, maternal plasma levels, pH, and lipid 
solubility [88]. To date, there are three animal studies that explore the effects of BPs during 
lactation, however similar to studies assessing BP safety during pregnancy, recommendations 
regarding the use of BP during lactation remain inconclusive [89-91]. With regards to human data, 
there is a dearth of case studies reporting the effects of BPs prior to or during lactation. Of the case 
studies that are available, both mother and infant did not demonstrate serious adverse effects [68-
70]. Based on the data available in the literature, there remains considerable debate about the 
effects of BPs on the maternal, fetal, and neonatal skeleton, and how these affects may change 
with timing of exposure.  To assess this clinical scenario, Brtl/+ females were used to identify the 
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maternal skeletal changes during pregnancy and lactation in OI and how these skeletal changes 
were affected with PAM intervention. We also explored how treating the maternal skeleton with 
PAM during pregnancy and lactation might affect fetal and neonatal skeleton development. Four 
possible routes of fetal and neonatal PAM exposure that might alter bone metabolism were 
considered: 1) PAM can cross the placenta if the mother is treated during pregnancy. 2) PAM can 
diffuse into the breast milk if the mother is treated during lactation. 3) Because of BPs long half-
life, treating the maternal skeleton prior to conception may expose fetal and neonatal bone to PAM 
through their recycling secondary to maternal bone resorption. 4) PAM can indirectly interfere 
with fetal and neonatal development by inhibiting maternal bone resorption. This in return can 
disrupt calcium homeostasis and prevent offspring from receiving the necessary calcium supply 
for healthy bone development.  
Our results showed that pregnancy led to maternal trabecular gains in vertebral bone mass, while 
lactation induced maternal cortical and trabecular bone loss in both vertebra and femur. When the 
maternal skeleton was treated with PAM prior to conception, bone mass gains due to pregnancy 
were amplified and lactation-induced bone loss was prevented. This protective effect was more 
modest when given during pregnancy (E15) and ceased to exist when PAM was given during the 
late stages of lactation. Furthermore, pregnancy induced osteocyte osteolysis which was unaffected 
with PAM treatment. Despite preventing lactation-induced maternal bone loss, no negative skeletal 
effects of BPs on offspring were observed. These findings indicate that during this period of 
significant imbalance between bone resorption and formation, BPs can help reduced the risk of 
maternal bone fragility in OI by inhibiting lactation-induced bone resorption without affecting 
bone development in their offspring.  
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Chapter 3: Low Dose of Bisphosphonate Enhances Sclerostin Antibody-Induced Trabecular 
Bone Mass Gains in Brtl/+ Osteogenesis Imperfecta Mouse Model 
Chapter 3 addresses the poor bone response from antiresorptive and anabolic monotherapy in cases 
associated with severely low bone mass. Antiresorptive and anabolic monotherapy as described 
earlier, have shown a beneficial response in bone mass in both animal models and clinical studies. 
However, the bone mass gains produced from antiresorptive therapies like BPs do not always yield 
a decrease in fracture incidence. While SclAb has gained interest as a promising anabolic approach 
for the treatment of OI, in severe cases of OI, less promising results were observed [60]. Thus, we 
have proposed a combination of antiresorptive and anabolic treatments for these challenging 
clinical cases.  
The rationale for combining anabolic and antiresorptive agents is that if bone formation is 
stimulated by an anabolic agent while bone resorption is inhibited by an antiresorptive agent, the 
concomitant combination therapy might attain superior bone mass and strength effects compared 
to monotherapy. Clinical studies have observed the effects of anabolic and antiresorptive 
treatments and demonstrated their superiority over monotherapy in improving BMD [92-94]. 
However, there is a clear difference in the data found between the order, timing and dosage of 
treatment. In an OI mouse model, BP treatment helped preserve SclAb-attributed bone mass gains 
following cessation of drug [53]. Alternatively, when SclAb was administered following BP in 
aged ovariectomized rats, gains in bone mass with SclAb were unaffected by prior BP exposure 
[45]. However, in another OI mouse model, when SclAb was combined with zoledronic acid a 
saturation effect was observed from zoledronate treatment that no additional gains in bone mass 
were observed with SclAb [95].  
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In this study, rapidly growing Brtl/+ mice were treated with PAM and SclAb to assess the 
immediate and long-term effects of combination therapy in a model of moderately-severe OI. In 
order to minimize the effects of PAM, we chose dosages that represent 10% (0.3 mg/kg) and 20% 
(0.625 mg/kg) of dosage shown to induce trabecular retention in growing mice [96]. Sclerostin 
antibody was chosen at a dose that consistently induced an anabolic effect in our prior studies in 
the Brtl mouse [47, 48]. Our goal in designing this study was to allow both drugs to work together 
rather than creating a saturation effect from one of the drugs.  
Results from this study showed that following one cycle of combination therapy, a single dose of 
antiresorptive PAM in combination with anabolic SclAb led to a cumulative effect on bone mass, 
but each through independent means. PAM retention mechanism led to an increase in trabecular 
number as the dosage increased while no additional gains in number were observed with SclAb. 
Conversely, while PAM showed no significant effect on trabecular thickness, SclAb induced a 
consistent trabecular thickening across all BP dosages. Chronic effects of concurrent 
administration of BP and SclAb revealed that accumulating cycles conferred synergistic gains in 
trabecular mass and vertebral stiffness, suggesting a distinct advantage of both therapies combined. 
Cortical gains in mass and strength occurred through SclAb alone, independent of presence of BP. 
In conclusion, these preclinical results support the scientific hypothesis that a single dose of 
antiresorptive BP facilitated the anabolic action of SclAb by increasing availability of surfaces for 
new bone formation via retention of primary trabeculae that would otherwise be remodeled. 
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Thesis Contributions 
Given the lack of treatment options for patients with severe OI and the lack of knowledge regarding 
the effects of BPs during pregnancy and lactation on both the maternal and fetal/neonatal skeleton, 
this thesis provides valuable insight that can help develop patient-specific treatment plans to 
optimize the effects of current and promising therapies for both premenopausal women and 
pediatric OI. To date, various pharmaceutical interventions have been studied extensively in the 
pediatric population since bone fragility is high prior to achieving peak bone mass. The aging 
population has also been extensively evaluated with antiresorptive and anabolic treatments due to 
increased risk for developing osteoporosis. Although studies have shown the benefits in treating 
young adults, post-puberty, bone fragility in OI is relatively low during this time.  
Little is known about bone fragility in premenopausal women who become pregnant and lactate 
their offspring. It is known that the maternal skeleton experiences significant bone loss during 
pregnancy and lactation in order to provide the necessary calcium supply to their developing 
offspring. Although significant bone mass gains have been observed months after lactation, this 
period of skeletal vulnerability can increase fracture risk especially in women associated with an 
underlying metabolic bone disorder like OI. In Chapter 2, we addressed this clinical challenge by 
treating Brtl/+ mice with a single clinical dose of PAM at one timepoint during pregnancy and 
lactation. The resulting temporal effects on bone metabolism from a single BP dose administered 
during pregnancy or lactation provide a treatment window for when BPs are most effective on the 
maternal skeleton with no adverse effects on fetal/neonatal bone development. Thus, in cases 
where the maternal skeleton can benefit from BP intervention such as pregnancy and lactation- 
associated osteoporosis (PLO), glucocorticoid-induced osteoporosis, or hypercalcemia, this 
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optimization window can provide insight on time points of intervention that can yield beneficial 
clinical outcomes.   
Another gap in the OI bone fragility timeline is the lack of promising treatment options for children 
with severe OI. Although a variety of studies have evaluated the effects of antiresorptive and 
anabolic monotherapy in pediatric OI, no single therapy has led to significant improvements in 
severe OI. In Chapter 3 we addressed this clinical challenge by treating rapidly growing Brtl/+ 
mice with a carefully designed PAM and SclAb combination therapy. The synergistic effects 
observed from this study provide a potential treatment plan for patients that lack structural bone 
surface that will not benefit from monotherapy alone. By taking advantage of the antiresorptive 
effects of PAM and the anabolic effects of SclAb, we can prevent the conversion of primary to 
secondary spongiosa in a growing model so that SclAb can have enough surface to build on.  
Through the presented work in this thesis I hope to further the field into developing more strategic 
and thought-out therapeutic interventions. Rather than developing new pharmacological drugs to 
achieve a “one treatment fits all” solution, we, the community, can design novel and personalized 
treatment interventions, especially for challenging clinical scenarios with an underlying metabolic 
bone disease. By understanding the changes in bone metabolism of the clinical condition under 
investigation and combining it with our understanding of the targeted pathways of antiresorptive 
and anabolic therapies, we can strategically and systematically optimize bone therapeutics so that 
the best clinical outcome can be achieved.  
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Chapter 2 Bisphosphonate Treatment Intervention during Pregnancy and Lactation Leads 
to Temporal Inhibition of Lactation-Induced Bone Loss on the Maternal Skeleton 
 
Introduction 
Pregnancy and lactation are known as periods of significant maternal bone loss due to changes in 
calcium homeostasis required for fetal bone mineralization and breast milk production. Since the 
decrease of maternal bone has been shown to be transitory, this reproductive period has not been 
clearly associated with osteoporosis or increased maternal fracture risk [97]. However, it remains 
uncertain if these physiologic conditions define a period of vulnerability for the maternal skeleton 
associated with a rare underlying metabolic bone disorder like osteogenesis imperfecta (OI). 
Limited information on the maternal skeletal outcome following pregnancy and lactation in 
women with OI is known [98-100], however fractures and other complications have been reported 
[56, 101-103]. Currently, bisphosphonates (BPs) are the most widely prescribed anti-resorptive for 
the treatment of metabolic bone diseases associated with excessive bone resorption [18, 104]. 
Through their high affinity for calcium ions, these synthetic analogues bind to hydroxyapatite 
crystals within the bone matrix to mediate an inhibitory effect on active osteoclasts to decrease 
bone turnover and increase bone mineral density [20-26]. Although the majority of patients treated 
with BPs are postmenopausal, children and women of childbearing age are increasingly being 
prescribed these treatments [105-107]. Because BPs can remain sequestered within the bone matrix 
until they are taken up by osteoclasts, there is raising concern that fetal exposure could occur in 
cases where the mother has been subjected to BP treatment prior to conception. Additionally, it 
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has been shown that disease-modifying medication has the potential to pass from the mother's 
blood stream into the breast milk and reach the nursing infant [74-77]. Although clinical case 
studies have reported the benefits of BPs for the treatment of pregnancy and lactation-associated 
osteoporosis (PLO), glucocorticoid- induced osteoporosis, hypercalcemia and other complications 
during pregnancy and lactation [106, 108-111], data on the effects of BP exposure during 
pregnancy or lactation remains limited. 
Currently BPs have been classified by the FDA as holding a category C pregnancy risk because 
animal reproduction studies have shown adverse effects, and no adequate and well-controlled 
studies in humans have been reported [112]. Our current knowledge about the effect of BPs on 
pregnancy is based almost entirely on animal studies, which have shown that these drugs are 
capable of crossing the placenta, thus putting the fetus at risk for exposure in utero [79-82]. 
Although these animal studies showed that BP exposure led to low birth weight, 
underdevelopment, and skeletal retardation, toxic levels were administered in order to assess their 
safety during pregnancy and lactation. Two toxicity animal studies have also explored the effects 
of BPs during lactation where severe and mild hypocalcaemia was observed due to disruption in 
maternal calcium metabolism [89, 113-115]. Of the case studies that are available, both mother 
and infant did not demonstrate serious adverse effects, however a few studies did report low birth 
weight, low gestational age and transient asymptomatic hypocalcaemia in the offspring [83-87, 
116-119].   
Recommendations regarding the use of BPs during lactation are often conflicting since it is not 
entirely known how much of a given drug passes the placenta or diffuses into breast milk and 
studies don’t agree on a common conclusion. Thus, there remains a need for developing systematic 
studies on BP effect when treating the maternal skeleton during a period of demanding metabolic 
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bone changes that are critical for the skeletal development of their offspring. In the present study 
we sought to determine a therapeutic window for when BPs are most potent on the maternal 
skeleton and how exposure affects fetal and neonatal development. We hypothesized that BP 
resorption effects on the maternal skeleton will be highly dependent on the time of administration 
since bone metabolism is constantly changing throughout pregnancy and lactation. Offspring are 
at risk of BP exposure if BPs cross the placenta or diffuse into the breast milk even if the mother 
has stopped treatment prior to conception, due to BPs long-half-life and their release into the 
bloodstream following maternal bone resorption. Additionally, since the maternal skeleton serves 
as a calcium reservoir to maintain calcium homeostasis during ossification and mineralization of 
their offspring, BPs can interfere with maintaining this balance and indirectly affect fetal/neonatal 
bone development. To explore these questions, we tested BP effects using a single injection of 
pamidronate at different stages of pregnancy and lactation in Brtl/+ dams harboring an OI-causing 
defect. Our knock-in mouse model reproduces the phenotype of moderately severe type IV OI [64-
66] and has been used to explore therapeutic efficacy of anti-resorptive and anabolic interventions 
in growing and aged mice [47, 48, 50, 53, 120, 121]. Additionally, to explore the sequela of events 
induced by BP on the maternal skeleton, we analyzed fetal and neonatal bone development in 
genotyped and sexed offspring from treated and untreated Brtl/+ dams. In the present study, a 
temporal effect on the preservation of bone mass was observed when BP was administered at 
different stages of pregnancy and lactation. When BP treatment was administered prior to 
conception, lactation-induced maternal bone loss was prevented while BP-induced skeletal 
preservation was less effective when administered during the late stages of lactation. Despite 
preventing lactation-induced bone loss, no adverse effect on fetal and neonatal bone development 
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was found, suggesting additional sources of calcium are capable of responding to the demands 
placed on the maternal skeletal. 
 
Materials and Methods 
Experimental design 
Brtl/+ mice with a mixed background of SV129/CD-1/C57BL/6S were derived from heterozygous 
Brtl/+ and WT parental strains [64]. To identify temporal maternal skeletal changes during 
pregnancy and lactation in OI and how these skeletal changes are affected by BPs, female Brtl/+ 
(n = 10/group) mice between 12 and 18 week of age were randomly assigned to receive a single 
tail vein injection of either pamidronate (PAM 3 mg/kg) or vehicle (PBS) during one of five time 
points (prior to conception (PC), gestation day 15 (E15), lactation day 1 (D1), lactation day 10 
(D10) or lactation day 15 (D15)). This single PAM dose represents a standard clinical dosage that 
has been used during pregnancy [106]. For successful timed pregnancies, female Brtl/+ were mated 
with experienced male WT breeders and pregnancy was assessed by examining for a vaginal plug. 
Pregnant mice were caged individually and were continued on standard chow diet (5L0D, PicoLab, 
St. Louis, MO, USA) throughout pregnancy and lactation. Standard chow contained a calcium 
concentration of 6.6% and 4.6 IU/gm of vitamin D. Mothers, along with litter, were euthanized at 
birth to isolate the effects of pregnancy. To assess both pregnancy and lactation effects, mother 
and litter were euthanized at weaning (D21). Age- matched virgin female Brtl/+ mice (n = 10) 
were assessed to establish a skeletal baseline uninfluenced by pregnancy and lactation. A summary 
of the experimental design for maternal and neonatal assessment of skeletal changes during 
pregnancy and lactation under the influence of BPs is shown in Figure 2.1. All protocols and 
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procedures were approved by the University of Michigan’s Committee on Use and Care of 
Animals.  
Non-therapeutic fluorescent bisphosphonate probe 
A single injection of commercially available far-red fluorescent pamidronate (FRFP) Osteosense-
680EX (Perkin Elmer, Bedford, MA, USA) was administered in Brtl/+ pregnant (gestation day 19) 
and lactating dams (lactation day 1) to assess if BPs crossed the placenta and diffused into the 
mammary glands. The administered dosage was 2nmols of FRFP buffered in PBS in a tail vein 
injection volume of 150 μL. Controls received a 150 µL tail vein injection of PBS.  
FRFP Imaging 
To assess FRFP binding in fetal skeleton, pregnant Brtl/+ dams (gestation day 19) were euthanized 
within 24 hours of FRFP injection. Embryos were fresh frozen in chilled isopentane at −70°C in 
O.C.T compound embedding medium (Fisher Chemical Co., Santa Clara, CA, USA) and stored at 
-80°C. To assess if BPs diffuse into the breast milk during lactation, the mammary glands from 
Brtl/+ dams at day 1 of lactation were fresh frozen and stored similar to the embryos. Frozen 
samples were sectioned to a thickness of 10µm using the Kawamoto film technique [122] and a 
Leica CM3050S cryostat (Leica Microsystems, Germany). Fluorescent images from tissue 
sections were acquired with a 20x dry objective using a Zeiss Axiovert 200M inverted microscope 
(Carl Zeiss, Germany). To assess diffusion into breastmilk a similar protocol was carried out. 
However, prior to euthanizing Brtl/+ dams who were in lactation, dams were imaged in vivo with 
the Li-COR Pearl Animal Imaging.  
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Micro-computed tomography (μCT) 
To analyze maternal and neonatal bone morphological changes after pregnancy and lactation, 
excised L3 vertebrae and right femora were first fixed in 10% neutral buffered formalin. Following 
fixation, both vertebrae and femurs were scanned in water using high-resolution μCT (Brucker 
Skyscan 1176, Kontich, Belgium). Image acquisition was performed at 50 kV and 800 μA with a 
0.3° rotation step and a 0.25 mm aluminum filter for filtration of beam hardening artifacts.  
Manufacturer-provided hydroxyapatite phantoms were scanned with the same parameters to 
calibrate and compute volumetric BMD. Individual two-dimensional cross-sectional images were 
reconstructed into three-dimensional volumes with 9 μm isotropic voxel size using NRecon 
software (version 1.6.5.8, Bruker).  
Two volumes of interest were established to analyze the effect of BPs during pregnancy and 
lactation on the femur. A 2 mm (maternal) and 1 mm (neonatal) VOI was centered midway 
between the lateral third trochanter and the distal femoral growth plate for cortical analysis and 
segmented using a user-defined global threshold derived from calculating the average thresholds 
over a range of samples. For trabecular analysis, a VOI spanning 15% of total femoral length for 
maternal bone and 7% for neonatal bone was placed at the metaphysis just proximal to the distal 
growth plate. Manual contours were used to isolate the trabecular compartment and further 
segmentation was performed using an automatic adaptive thresholding algorithm.  
For vertebral analysis, a VOI was placed between the cranial and caudal endplates of maternal and 
neonatal L3 vertebrae. Vertebral cortical and trabecular bone were separated through manual 
contouring to denote the outer and inner boundaries of the cortex and segmented with automatic 
adaptive thresholding. The areas of interest were analyzed with CTAn software (version 1.15.4.0, 
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Bruker). Bone architecture parameters analyzed include: (trabecular number – TbN, trabecular 
thickness – TbTh, bone volume fraction – BV/TV, cortical thickness – CTh, and bone mineral 
density – BMD). Representative femoral and vertebral isosurfaces were obtained using 
commercially available software (MicroView Advanced Bone Analysis Application, GE 
Healthcare Pre-Clinical Imaging, London, ON, Canada).     
Backscatter scanning electron microscopy 
Previous studies have shown that osteocyte osteolysis plays an important role during lactation 
[123-126]. To assess physiologic osteocytic remodeling in our study, lacunar area was measured 
on maternal cortical bone of right femora. Following microCT imaging, maternal right femora 
were embedded without decalcification in methyl methacrylate and sectioned transversely below 
the lateral third trochanter using an Isomet low-speed diamond saw (Buehler Ltd., Lake Bluff, 
NY). Two hundred-micron sections were then polished and mounted on aluminum stubs using an 
alcoholic colloidal graphite solution. Images of osteocyte lacunae on the sectioned bone surface 
were acquired with a scanning electron microscope equipped with a backscattered electron 
detector (BSEM, Tescan MIRA3 FEG- SEM, Czech) at 30 kV accelerating voltage, 300 pA 
current, and 10 mm working distance. Acquired high contrast images were then converted into 
binary mask using ImageJ (NIH, Bethesda, MD) and areas were measured for all lacunae in the 
anterior, posterior, lateral and medial quadrant of the femoral cortex. 
Biomechanical testing 
To assess the mechanical effects during pregnancy and lactation and the influence of BPs during 
these events, maternal L5 vertebra and left femora were loaded to failure in compression and four-
point bending, respectively, using an MTS 858 Mini-Bionix servo-hydraulic testing system (MTS 
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Systems Corp., Eden Prairie, MN, USA). All specimens were kept hydrated in lactated ringer's 
solution (LRS) prior to mechanical testing. The vertebral body was vertically aligned along its 
loading axis with an alignment pin (attached to lower platen and extending through the spinal 
column) and compressed to failure at a displacement rate of 0.05 mm/second. For four-point 
bending, the posterior surface of the femur was oriented in tension and the mid-diaphysis was 
loaded to failure at a displacement rate of 0.5 mm/second. Force and vertical displacements were 
continuously recorded throughout each test by a 50 lb load cell (Sensotec, Columbus, OH, USA) 
and an external linear variable differential transducer (LVDT; Lucas Schavitts, Hampton, VA, 
USA), respectively. A custom- developed LABVIEW program was used to calculate the 
mechanical properties for both tissues.  
Tartrate‐resistant acid phosphatase staining 
Qualitatively, histochemical staining of the biochemical marker tartrate-resistant acidic 
phosphatase (TRAP) has been used to identify osteoclast activity. To assess TRAP activity in 
maternal and neonatal trabecular bone, right proximal tibiae were fixed (4% neutral buffered 
formalin), decalcified (10% EDTA for 21 days) and embedded in paraffin. Ribbons of serial 
sections (6μm) were cut with an automated Leica RM2255 (Leica, Wetzlar, Germany) rotary 
microtome and disposable low profile stainless steel blades (Accu-Edge, 4689).  Collected sections 
were mounted on Superfrost/Plus glass slides (Fisher, Pittsburgh, PA., USA) and left to dry 
overnight on a 40°C slide warmer. Staining for TRAP was carried out with an Acid Phosphatase, 
Leukocyte (TRAP) Kit (Sigma- Aldrich, St. Louis, MO., USA) according to the manufacturer’s 
instructions. Images were acquired using an upright microscope (Nikon Eclipse Ni-U) associated 
with a DS-Fi2 digital camera, NIS BR software (Nikon France, Champigny-sur-Marne, France) 
and a 20x dry objective. Histomorphometric analysis of maternal osteoclast activity was acquired 
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from two ROIs; the first was placed proximal to the growth plate at a span of 5 mm, while the 
second spanned 12.5 mm placed 5 mm distal to the growth plate. For neonates, due to high 
mineralized bone concentrated below the growth plate, a single 17.5 mm ROI was placed 12.5 mm 
distal the growth plate. In addition, neonatal osteoclast activity from mothers exposed to BPs at 
timepoints PC, E15 and D1 were analyzed to assess osteoclast activity on skeletal development 
when exposed to BPs through different pathways. When dams are treated with PAM PC, BP 
recycling resulting from bone resorption during periods of high calcium demand can expose 
offspring during both the embryonic or neonatal stage prior to weaning. Treating dams with PAM 
during gestation can lead to BPs to cross the placenta and expose the embryo to PAM (E15). Lastly, 
PAM treatment during lactation leads to potential diffusion of BPs into the breast milk, exposing 
neonates to PAM during a time they highly depend on their mothers for survival (D1). Analysis 
for both mothers and neonates was performed using Bioquant software (Bioquant Image Analysis 
Corporation, Nashville, TN., USA).  
Statistics 
Maternal bone architecture data are reported through box plots where treated (grey) groups are 
superimposed onto untreated (white) groups. Maternal variations in bone architecture, 
biomechanics, osteoclasts osteolysis, and osteoclast activity between untreated/treated groups and 
virgin controls were determined using a one-way ANOVA followed by Holm–Sidak test for 
multiple comparison. To determine differences between untreated and treated groups a two-way 
ANOVA was applied to analyze both maternal and neonatal parameters. Differences with p-values 
<0.05 were considered significant. All statistical analyses were carried out using Graph Pad Prism 
(version 7.04, San Diego, CA, USA) 
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Results 
Maternal and neonatal body weight are not affected with pamidronate treatment 
Maternal body weight increased during pregnancy (through E15), decreased immediately 
following birth (D1) and increased again through weaning (D15) (Figure 2.2A) in both PAM and 
PBS treated groups. By the end of lactation (D21), maternal body weight reached a common value 
regardless of PAM treatment status or time of treatment (Figure 2.2B). At 21 days of age, the body 
mass of genotyped female pups from PBS-treated dams did not differ from the body weight of 
genotyped female pups from PAM-treated dams. The same observations were seen in genotyped 
male pups. Furthermore, consistent with the reduced body size in OI, the body mass of HET pups 
was significantly lower than the body weight of WT pups in both females and males. This suggests 
that neonatal and maternal body mass was not affected by maternal PAM exposure during bone 
formation. The number of sudden deaths of pups in the litters was evenly distributed between 
PAM-treated (n = 9) and PBS-treated groups (n = 11), consistent with prior reports of spontaneous 
deaths in Brtl/+ pups ([64]). In addition, one PAM and two PBS treated dams were euthanized due 
to morbidity prior to the end of the experiment.   
Pamidronate effects on pregnacy and lactation-induced bone changes are highly dependent on 
time of treatment 
In Brtl/+ dams, pregnancy alone significantly increased vertebral Tb.N by 37% but significantly 
decreased Tb.Th by 10%, resulting in an overall increase in maternal bone volume fraction of 28% 
(Figure 2.3A; Treatment Timepoint PC; End Timepoint Birth) . The femur was less susceptible to 
these effects, as pregnancy had no effect on Tb.N but significantly decreased Tb.Th (7%), resulting 
in a 15% net bone loss (Figure 2.3B; Treatment Timepoint PC; End Timepoint Birth). Conversely, 
lactation induced a loss in Tb.N in both vertebra (7%) and femur (39%) as seen in Figure 2.3A and 
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Figure 2.3B (Treatment Timepoint PC-D15; End Timepoint Weaning). Together, these changes 
led to a 13% loss of vertebral bone volume fraction and an even greater femoral loss of 43% 
compared to virgin dams. When Brtl/+ dams were treated prior to conception with PAM, greater 
gains in vertebral Tb.N were obtained following pregnancy while no significant further gains were 
observed in the femur when compared to PBS- treated dams. Strikingly, when dams were carried 
out to the end of lactation (weaning of their pups at day 21), PAM induced a treatment-induced 
preservation of bone volume fraction through retained Tb.N that was directly related to timing of 
injection in both vertebra and femur. A modest preservation of bone mass was observed in the 
vertebra when PAM was administered prior to conception while significant gains of 58% were 
observed in the femur. PAM had no effect on Tb.Th regardless of time of treatment. In the cortical 
structure, pregnancy alone did not induce changes in vertebral or femoral C.Th, however, by 
weaned date, C.Th was reduced 16% and 10% in the vertebra and femur, respectively. Despite 
preservation of trabecular bone mass during the early stages of pregnancy and lactation (PC, E15 
and D1) with PAM intervention, preservation of C.Th was only observed when PAM was 
administered prior to conception in both the vertebra (Figure 2.3C; Treatment Timepoint PC; End 
Timepoint Weaning) and the femur (Figure 2.3D; Treatment Timepoint PC; End Timepoint 
Weaning).  
To qualitatively analyze the effects of PAM when administered at different stages of pregnancy 
and lactation, representative microCT images were extracted from virgin females and from dams 
at D21 post-weaning to visualize changes in maternal trabecular and cortical bone morphology. 
Lactation- induced bone loss was observed in both the vertebra and femur of PBS- treated dams 
(Figure 2.3E). When PAM was administered prior to conception, pregnancy and lactation-induced 
bone loss was completely prevented in Brtl/+ dams (Figure 2.3F). When PAM was administered 
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at E15 during pregnancy and D1 of lactation, a temporal preservation of bone mass was observed. 
No further preservation of trabecular structure was observed when dams were treated with PAM 
at D10 and D15 of lactation, suggesting trabecular bone loss had already occurred prior to this 
time point.  
PAM-induced preservation of trabecular and cortical bone increases stiffness but not strength 
during pregnancy and lactation  
Like the response seen in trabecular bone, a temporal effect was also observed in stiffness for both 
the vertebra and femur of PAM-treated dams. With pregnancy alone, a 57% increase in vertebral 
stiffness was observed in PBS-treated dams (Figure 2.4A), consistent with pregnancy-induced 
gains observed in Tb.N. No stiffness changes were observed in the femur following pregnancy 
alone, but a 10% femoral stiffness loss was observed by the end of lactation (Figure 2.4B).  When 
PAM was administered prior to conception, vertebral stiffness in dams increased by 151% 
following pregnancy alone while a 50% increase was observed when assessed following lactation. 
Femoral stiffness assessed at birth and treated prior to conception showed an increase of 15% and 
an increase of 21% when assessed following lactation compared to virgin dams. Treatment with 
PAM induced a temporal effect on both vertebral and femoral stiffness when treated with PAM at 
different timepoints during pregnancy and lactation similar to the protective effect observed in 
their trabecular structure. Unlike stiffness, ultimate load in the vertebra did not show a temporal 
effect with PAM treatment. Instead, when dams were treated with PAM prior to conception and 
assessed at birth, a sustained effect was observed in vertebral max load, but an overall 26% was 
noted by weaned date regardless of PAM timepoint administration. Unlike the vertebra, a temporal 
effect with PAM treatment was observed in femoral ultimate load to failure when assessed at 
weaning. When dams were treated with PAM prior to conception a 6% increase in ultimate load 
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to failure was observed at birth, however, when assessed at weaning ultimate load decreased by 
10% compared to virgin dams. This protective effect on femoral max load ceased to exist when 
PAM was administered at late stages of lactation.  
BPs cross the placenta and diffuse into the breast milk 
To assess if BPs cross the placenta, a fluorescent bisphosphonate imaging agent (Osteosense 
680EX) was administered when Brtl/+ were in late stages of gestation (E19). As seen in Figure 
2.5A fluorescent images of the fetal vertebral body showed localization of BPs during late stages 
of gestation, confirming that BPs can cross the placenta. Similarly, non-therapeutic BP was 
administered in Brtl/+ dams during early stages of lactation (D1) to assess if BPs diffuse into the 
breastmilk.  In Figure 2.5B, fluorescent images of the maternal mammary glands verified the 
diffusion of BPs into the breastmilk.  
Neonates at birth and weaning did not show skeletal adverse effects from maternal pamidronate 
exposure 
Pregnancy and lactation represent a challenging period for the maternal skeleton as high demands 
of calcium are required for the healthy development of the neonatal skeleton. Since pregnancy and 
lactation-induced bone loss was prevented in PAM-treated dams, assessing neonatal skeletal 
development was imperative. At birth, following maternal PAM exposure during pregnancy alone, 
neonates (1 day of age) from dams treated with PAM prior to conception showed no effects from 
BP exposure during their early stages of skeletal formation as no differences in BMD were 
observed in either the vertebra or the femur (Figure 2.6A). Following maternal PAM exposure 
during pregnancy and lactation, at 21 days of age, sexed Brtl/+ and WT pups from PAM-treated 
dams continued to show no effect from BP exposure on trabecular and cortical structures (Figure 
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2.6B). To further assess that PAM exposure during pregnancy and lactation did not induce any 
adverse effects in the neonate’s skeletal formation, Safranin O-stained sections reveal no 
morphological differences between pups from PBS and PAM treated dams (Figure 2.6C). Thus, 
despite preventing pregnancy and lactation-induced bone loss, no effects were observed in pups 
from PAM-treated dams compared to pups from PBS-treated dams.  
Pamidronate increases maternal osteoclast number and surface but has no effect on neonates 
exposed to BPs during early stage of skeletal formation and lactation 
To examine the presence of osteoclasts following maternal PAM exposure during pregnancy and 
lactation, mature osteoclasts positive for TRAP staining were identified in maternal tibia for all 
groups carried out through the end of lactation. TRAP+ mature osteoclasts (Figure 2.7A; N.Oc/BS) 
were present in both PAM and PBS-treated dams, albeit statistically more in PAM treated Brtl/+ 
dams. However, no differences were observed in osteoclast- surface coverage (Figure 2.7A; 
Oc.S/BS) between PAM and PBS-treated dams. To further assess the effect of the potential 
exposure to PAM during skeletal development, osteoclast activity in day 21 neonates from PBS 
and PAM treated dams was also analyzed following maternal intervention at prior to conception, 
E15 and D1. No differences in osteoclasts number (Figure 2.7B; N.Oc/BS) and surface coverage 
(Figure 2.7B; Oc.S/BS) between neonates from PAM and PBS-treated dams were observed 
suggesting that either our PAM dosage provides a low exposure risk during crucial periods of 
skeletal development or that PAM has not yet taken an effect on neonatal bone.  
Pamidronate did not further increase osteocyte lacunar area during pregnancy 
Backscattering imagining was used to analyze PAM effects on maternal osteocyte osteolysis 
during pregnancy and lactation at standard locations of the femoral cortical bone (Figure 2.8A). 
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Consistent with other studies, a significant increase in osteocyte osteolysis was observed following 
pregnancy in PBS- treated dams (Figure 2.8B). A similar increase was observed when dams were 
treated with PAM, suggesting that BP had no effect on lacunar size. By the end of lactation, when 
calcium demand is low, osteocyte osteolysis decreased and PAM continued to show no effect. 
Representative images of the differences in lacunar area under these conditions are shown in Figure 
2.7C.  
 
Discussion 
The present study shows that pregnancy led to maternal gains in vertebral trabecular bone mass 
observed at parturition, while lactation induced maternal cortical and trabecular bone loss in both 
vertebra and femur observed at weaning in Brtl/+ mice harboring an OI-inducing Gly->Cys 
mutation in col1a1. BP intervention led to a temporal retention of maternal cortical and trabecular 
bone in both vertebra and femur. When PAM was administered prior to conception (PC), bone 
mass gains due to pregnancy were amplified and lactation-induced bone loss was prevented. This 
protective effect was more modest when given during pregnancy (E15) and ceased to exist in the 
late stages of lactation (D10 and D15). Furthermore, pregnancy induced osteocyte osteolysis which 
was unaffected with bisphosphonate treatment. Despite preventing lactation-induced maternal 
bone loss, no negative skeletal effects of BPs on offspring were observed. In view of the increasing 
use of BPs in premenopausal women to treat diseases causing high rates of bone remodeling like 
OI, these findings provide important clinical insight on a systematic window for when BPs are 
most effective in preserving maternal bone mass and how maternal exposure may affect embryonic 
and neonatal skeletal development. 
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Current knowledge on the effect of BPs during pregnancy remains limited and is based almost 
entirely on animal toxicity studies that show transplacental effects of BPs [79-82]. Administration 
of alendronate (0.1mg/kg) during gestation days 11-20 in rats resulted in BP accumulation in fetal 
bone which led to low birth weight and decreased bone growth [79]. Additionally, embryonic 
lethality, severe underdevelopment and fetal skeletal retardation was observed in a reproduction 
toxicity study involving rats and rabbits where PAM therapy was administered at a dosage 10x 
higher than what is used clinically [80]. In another similar rat study, BPs induced tremors, dystocia 
and death in dams during parturition as a result of pronounced maternal hypocalcemia [81]. These 
adverse effects are likely dose related, however fewer studies exist that examine sub-toxic doses. 
No adverse maternal or offspring effects were observed in a rat and rabbit study using low dosages 
of icadronate, however when dosage was increased, dam death, retarded fetal ossification and 
abnormal tooth growth were noted [82]. Human data on BP effects during pregnancy is also 
limited. Scattered clinical cases reported uneventful pregnancies under BP treatment [68, 85, 106], 
but a few case studies did show lower gestational age at birth, small birth weight and increased 
rate of spontaneous abortions [127]. However, due to the rarity of these outcomes it was speculated 
that the effects could have been a result of maternal underlying conditions rather than BP itself 
[127]. 
To date, two animal toxicity studies have explored the effects of BPs during lactation. Both bovine 
and rat studies showed that BPs induce hypocalcaemia in response to the inhibition of lactation-
induced bone loss [89, 113]. In two pharmacological studies, BP treatment attenuated but did not 
prevent lactation-induced bone loss, however, no neonatal effects were reported [128, 129]. 
Several studies have shown evidence of post-lactation recovery of maternal bone loss [130-132] 
which may occur independent of preceding resorption events.  When zoledronate was administered 
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at the beginning of lactation, bone formation persisted after forced weaning despite prevention of 
lactation-induced bone loss [133]. With regards to human data, there is a dearth of case studies 
reporting the effects of BPs when administered prior to, or during lactation. Of the case studies 
that are available, both mother and infant did not demonstrate serious adverse effects [117, 119, 
127, 134], however one report cited transient asymptomatic hypocalcaemia of the newborn [116]. 
The present study differs from prior animal studies by using sub-clinical doses compared to the 
high doses previously used to evaluate BP safety during pregnancy and lactation.  Due to the 
differing bone metabolic effects during pregnancy and lactation, our approach was to identify a 
window for when BPs are most effective at inhibiting bone loss without disrupting calcium 
homeostasis for fetal and neonatal growth in an OI mouse model. In the present study, pregnancy 
triggered a significant increase in trabecular bone volume fraction of Brtl/+ dams, similar to results 
observed in other animal studies [135, 136]. However, this increase in bone mass was only 
observed in the vertebral body as no significant differences were noted in the distal femur. During 
pregnancy, studies have shown that there is an accumulation of calcium in the maternal skeleton 
to serve as a calcium reservoir during lactation [137]. Other animal studies have also reported that 
following conception, there is an immediate accumulation of skeletal mass and its utilization 
begins around late pregnancy when the skeleton begins to form in the developing fetus [138, 139]. 
This process is then followed by a decline in maternal bone mass during lactation, as the neonatal 
skeleton begins to mineralize [140, 141].  Similar observations were observed in the present study, 
as trabecular bone mass significantly decreased in both the vertebra and distal femur during 
lactation. Although pregnancy did not induce any response on cortical bone, significant thinning 
of the cortical bone was observed following lactation, consistent with results reported in other 
studies [137, 140, 142].  
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Several studies have established that treating OI patients with BPs can decrease bone turnover and 
increase bone mineral density [20-26]. We have also shown in previous studies that BPs increase 
trabecular bone mass during growth through retention of trabecular number [53, 120, 121]. In this 
study, PAM intervention prior to conception (PC) prevented lactation-induced bone loss solely 
through retention in Tb.N as a net decrease in Tb.Th was observed with or without treatment. 
Retention of Tb.N was more modest when PAM was administered during pregnancy and early 
stages of lactation (E15 and D1) and ceased to exist in the late stages of lactation (D10 and D15). 
A less robust temporal effect was observed in cortical bone. These findings helped confirm that 
bone retention was clearly dependent on time of PAM administration.  
Increase in Tb.N following pregnancy drove gains in vertebral stiffness that were amplified with 
PAM intervention prior to conception. When the maternal skeleton was assessed following 
lactation, inhibition of lactation-induced bone loss with PAM when administered prior to 
conception (PC) led to significant preservation of vertebral and femoral stiffness. Similar 
observations were seen with PAM intervention during pregnancy (E15) and early stages of 
lactation (D1), while no differences were noted between treated and untreated dams at later stages 
of lactation (D10 and D15). Although no differences were observed in vertebral maximum load 
between treated and untreated dams when assessed at the end of lactation, a temporal effect was 
observed on femoral maximum load.   
Since we confirmed through FRFP that BPs were able to not only cross the placenta, but also 
diffuse into the breast milk  and that PAM intervention prevented lactation-induced bone loss in 
maternal bone, it was vital to assess if fetal and neonatal bone development was affected as well. 
Surprisingly, vertebral and femoral BMD of newborn WT and Brtl/+ mice (1 day of age) was 
unchanged when BP was administered prior to conception or during the embryonic stage. We 
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propose several possible means to alter fetal and neonatal bone metabolism through fetal and 
neonatal BP exposure, as well as altered maternal bone metabolism. Embryonic bone ossification 
has been reported to start near gestation day 14 [143]. Therefore, administration of PAM during 
early stages of fetal bone ossification may lead to BP exposure through placental crossing and 
localization on mineralized fetal bone during the embryonic stage. During lactation, it has also 
been well established that the demand for calcium is greatest at the beginning and decreases as 
offspring are introduced to outside food sources [130, 144]. As a result, when the maternal skeleton 
was treated with PAM at either D1, D10 or D15 of lactation, risk of exposure through diffusion 
into the breast milk was likely greatest at the beginning of lactation. Because of the long half-life 
of BPs, treating dams prior to conception may expose fetal and neonatal bone to PAM through 
bisphosphonate recycling secondary to maternal bone resorption. Alternatively, PAM can 
indirectly interfere with fetal and neonatal development secondary to inhibition of maternal bone 
resorption. Direct disruption of maternal calcium homeostasis through anti-resorptive effects may 
prevent offspring from receiving the necessary calcium supply for healthy bone development. 
Despite these potential exposures to PAM, Brtl/+ and WT offspring (21 days of age) from treated 
and untreated mothers showed no differences in trabecular bone mass or cortical thickness. These 
findings suggest that the single PAM exposure had no effect on skeletal development whether 
potentially transferred through the placenta, breast milk or BP recycling resulting from maternal 
bone resorption, or through altered maternal calcium homeostasis.  
It has been well established that for successful reproduction, it is vital that the mother gains an 
appropriate amount of weight during her pregnancy to provide adequate nutrients to allow the fetus 
to grow. In mice, pregnancy has been linked to hyperphagia resulting in linear weight gain until 
parturition [145]. However postpartum, studies have shown that pups begin eating solid food 
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midway through lactation which reflects a decrease in maternal weight and milk production [146]. 
We observed a linear increase in maternal weight during pregnancy and the first half of lactation. 
When maternal body mass was assessed at weaning, no differences were observed between PAM 
and PBS- treated dams, suggesting that BP exposure did not influence maternal food intake. 
Additionally, we also observed no adverse effects of PAM on neonatal weight at weaned date. 
These findings are in agreement with a study that evaluated the dependency of lactation-induced 
bone loss and post-lactation bone gains using zoledronate treatment where no adverse effects were 
observed on body weight of dams or ash weight of pups [133].  
We observed no difference in osteoclast surface or number in maternal tibiae between virgin 
controls and PBS-treated dams following lactation, despite the trabecular bone loss observed 
during this time. It is possible that we missed the window of high osteoclast activity since 
assessment was performed at time of weaning when bone turnover rate has slowed down (as seen 
from our D10 and D15 treated dams), however, no osteoclast assessment was performed following 
parturition. To support these findings, there is accumulating evidence that at the end of lactation 
there is a rapid reversal in maternal bone metabolism where bone formation greatly increases to 
begin to recover the maternal skeleton and rebuild its mineral storage in preparation for the next 
reproductive period [147]. In fact, female mice are in fertile estrus about 10 and 24 hours after 
giving birth, suggesting that this window of recovery is particularly short in mice. Furthermore,  
osteoclasts become apoptotic immediately with the cease of lactation [148]. Similarly, we did not 
observe an effect of PAM on osteoclast surface coverage, however greater osteoclast numbers 
were observed with treatment. In rats treated with a high dose of zoledronate, the number of 
osteoclasts increased significantly, and a number of other studies have shown that the number of 
osteoclasts could stay the same or even increase during BP treatment [149-151]. Alternatively, 
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another study showed that treatment with zoledronic acid reduced osteoclast surface when 
administered for both short and long durations [152].  
We assessed osteoclast activity in the neonates at wean date since it would allow us to evaluate 
the potential risk of PAM exposure on the role of octeoclasts during the ossification and 
mineralization stages of bone development. We explored timepoints PC, E15 and D1 since not 
only was maternal bone loss inhibited with PAM at these time points, but these time points dictate 
three possible routes of fetal and neonatal BP exposure. Considering that no differences on 
osteoclast surface and number were observed, we can conclude that in this model, BP exposure 
through recycling (PC), placental crossing (E15) and diffusion into the breast milk (D1) have no 
effect on embryonic and neonatal development. These limited effects might be due to two 
possibilities; embryonic and neonatal bone formation rate may exceed bone resorption, so 
osteoclasts don’t play a significant role during these early stages of bone development; our single 
PAM dosage was not enough to induce a significant biological effect.  
Although osteoclasts have been assumed to be primarily responsible for the removal of bone 
during calcium homeostasis, osteocytes have also been found to play a role during periods of 
increased calcium demand. While some studies have shown osteocytes play a role in calcium 
homeostasis during pregnancy and lactation [125, 153] others have not [154]. In our study, 
following pregnancy, Brtl/+ dams showed an increase in lacunar area which returned to baseline 
by end of lactation. While these changes were modest (16%) it is possible that lacunar area was 
higher during the earlier stages of lactation. Prior studies have shown osteocytic perilacunar and 
canalicular remodeling on the twelfth [124] and fourteenth day of lactation [155] while our 
observations were limited to parturition and weaning only. Most importantly, although maternal 
bone loss was prevented with PAM intervention, PAM showed no effect on osteocyte lacunar 
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remodeling during this crucial period of calcium demand. Conversely, others have shown 
inhibition of osteocyte osteolysis during lactation through calcitonin [156] and parathyroid 
hormone [157], which may reflect a direct action on the osteocytes through related signaling 
pathways.  
This study has several limitations. To assess history of BP therapy, a single PAM dosage was 
administered prior to conception, which does not reflect continuous BP accumulation in the 
maternal skeleton due to extensive treatment prior to conception in humans. Exploring a wider 
range of dosages will be important to fully assess the risk/benefit ratio of bone interventions during 
pregnancy and lactation. It is now well established that BPs have a long half-life and remain 
embedded in the bone matrix until liberated during osteoclastic resorption. Thus, fetal and neonatal 
BP effects might not be observed until later stages of rapid growth or adulthood when BPs are 
recycled through bone remodeling. Therefore, although no effects were observed on weaned pups, 
BP exposure risk should not be disregarded, and post-lactation assessment of neonatal growth 
should be considered. Despite inhibiting lactation-induced maternal bone mass, no effects were 
observed in fetal and neonatal bone development. However, we did not analyze calcium levels in 
mothers or their offspring to verify that PAM did not indirectly interfere with fetal and neonatal 
development secondary to inhibition of maternal bone resorption. Since it has been well 
established that pregnancy up-regulates intestinal calcium absorption [158], potential absorption 
changes in the presence of an anti-resorptive need to be addressed. Furthermore, treatment timing 
will vary depending on fracture risk diagnosis during pregnancy and lactation to attain the best 
clinical outcome.  
Aside from studying the effects of bone therapeutics in animal models for their translation into 
human clinical trials, studying any therapeutic effect during pregnancy and lactation raises several 
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challenges particularly since mice have a shorter gestation period (18 to 21 days) than humans 
(280 days). In this study, PAM was administered in mice on gestation day 15 which has been 
shown to be equivalent to week 8 of pregnancy in humans [159]. Although this timepoint 
represents the commencement of ossification in both timelines  [159, 160], the rapid skeletal 
development in mice significantly reduces their risk of possible transplacental exposures. As a 
result, PAM intervention in humans might lead to greater exposure risks in utero because 80% of 
their gestation period remains as oppose to 29% in mice. Once born, there is a wide variation in 
the developmental phases between mice and humans and correlating their relative ages can be 
determined through several factors [161]. For example, mice are weaned at day 21 post-birth while 
on average the weaning age for humans is about 6 months (180 days) [162]. Thus, in this study, 
neonatal mice were exposed to PAM on days 1, 10 and 15 of lactation which are equivalent to 9, 
86 and 129 days of age in humans, respectively. However, this correlation through weaned date 
may not accurately represent the metabolic bone state between both timelines, suggesting that 
further studies are necessary to assess these limitations.         
During pregnancy and lactation, significant demands are placed on the maternal skeleton to 
provide the necessary calcium supply required for fetal and neonatal bone formation. The changes 
in calcium homeostasis during these reproductive periods can influence a time-dependent BP 
effect on bone metabolism that is not captured in toxicology studies. The results in this study 
capture the temporal effects on bone metabolism when PAM was administered at different stages 
of pregnancy and lactation. Specifically, when the maternal skeleton was treated with PAM prior 
to conception, lactation-induced bone loss was prevented. Despite inhibiting lactation-induced 
bone loss with PAM treatment, no adverse effects were observed on neonatal bone development. 
Additionally, our results of osteocyte remodeling provided further insight to their contribution to 
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the regulation of calcium homeostasis during periods of high calcium demand from the maternal 
skeleton. We believe that calcium release from trabecular thinning and osteocyte osteolysis during 
pregnancy and potentially intestinal absorption (though not tested in this study) may have 
contributed to the healthy neonatal bone development observed here. These results offer a 
treatment window during pregnancy and lactation for when BPs are most effective and represent 
a further significant insight of the maternal changes in bone metabolism due to calcium 
homeostasis during this reproductive period. 
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Figures 
 
Figure 2.1: Assessing PAM effects at different stages of pregnancy and lactation in the maternal 
skeleton and its effects on offspring bone development from PAM exposure. A) Single injection of 
PAM treatment or PBS was administered during pregnancy and lactation in Brtl/+ dams. Virgin 
controls were used to establish a skeletal baseline uninfluenced by these reproductive periods. B) 
Proposed pathways of PAM exposure on fetal and skeleton bone development when the maternal 
skeleton is treated with BPs during the different stages of pregnancy and lactation. Not shown, 
potential indirect effect on calcium homeostasis from osteoclastic inhibition of maternal bone 
resorption during fetal and neonatal bone development.  
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Figure 2.2: Maternal and neonatal body weight are not affected with pamidronate treatment. A) 
Maternal body weight increased due to pregnancy and lactation and no body weight differences 
between PBS and PAM treated groups were observed. B) Greater gains in maternal body weight 
were not induced with PAM treatment. C) No differences in body weight of pups from PAM-treated 
dams and PBS-treated dams were observed. Results of Two-Way ANOVA factors: * p<0.05.  
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Figure 2.3: Pamidronate effects on pregnacy and lactation-induced bone changes are highly 
dependent on time of treatment. MicroCT analysis of the maternal Brtl/+ skeleton showed a 
temporal response to PAM intervention during pregnancy and lactation in both vertebra (A) and 
femur (B). A less robust temporal effect was observed in maternal cortical bone of both vertebra 
(C) and femur (D). Representative microCT isosurfaces of the distal femur metaphysis and the 
vertebral body reflect maternal bone structure in response to pregnancy and lactation in both 
untreated (E) and treated dams (F). Results of One-Way ANOVA factors: PAM and (PBS) 
compared to virgin controls: ++++ p<0.00005, +++ p<0.0005, ++ p<0.005, and + p<0.05. Results 
of Two-Way ANOVA factors: **** p<0.00005, *** p<0.0005, ** p<0.005, and * p<0.05.  
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Figure 2.4: PAM-induced preservation of trabecular and cortical bone increases stiffness but not 
strength during pregnancy and lactation. A) With PAM treatment PC, significant gains in 
vertebral stiffness were observed following pregnancy and lactation but no preservation in 
maximum load to fracture was observed. Similarly, in the femur, PAM showed a sustained effect 
on stiffness and also a loss in maximum load to fracture (B). Results of One-Wa4.y ANOVA 
factors: PAM and (PBS) compared to virgin controls: ++++ p<0.00005, +++ p<0.0005, ++ 
p<0.005, and + p<0.05. Results of Two-Way ANOVA factors: **** p<0.00005, *** p<0.0005, 
** p<0.005, and * p<0.05.  
 
 
 
 
 43 
 
Figure 2.5: BPs cross the placenta and diffuse into the breast milk. A) Fluorescent non-therapeutic 
BPs localized in fetal vertebral body during late stages of gestation and in the B) mammary gland 
during lactation. Control tissues from animals receiving PBS and imaged under identical 
acquisition settings show negative fluorescence.  
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Figure 2.6: Neonates at birth and weaning did not show skeletal adverse effects from maternal 
pamidronate exposure. A) No changes in vertebral and femoral bone mineral density were 
observed at birth in sexed Brtl/+ and WT offspring following PAM exposure during the embryonic 
stage. B) At 21 days of age, sexed Brtl/+ and WT neonates from PBS and PAM treated dams 
showed no change in bone mass or cortical thickness when exposed to PAM at different stages of 
their skeletal development. C) Representative histomorphometric images of neonatal femurs show 
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no adverse effect in bone formation from maternal PAM exposure. Results of Two-Way ANOVA 
factors: **** p<0.00005, *** p<0.0005, ** p<0.005, and * p<0.05.   
 
Figure 2.7: Pamidronate increases maternal osteoclast number and surface but has no effect on 
neonates exposed to BPs during early stage of skeletal formation and lactation. A) 
Histomorphometric quantification of TRAP-stained tibial bone sections showed that PAM 
treatment increased maternal osteoclast number and surface coverage compared to PBS-treated 
dams. No temporal effect was observed with PAM treatment. B) Osteoclast activity in pups from 
PAM- treated dams was not significantly altered with BP exposure at PC, E15 and D1 compared 
to pups from PBS- treated dams. Results of One-Way ANOVA factors: PAM and (PBS) compared 
to virgin controls: ++++ p<0.00005, +++ p<0.0005, ++ p<0.005, and + p<0.05. Results of Two-
Way ANOVA factors: **** p<0.00005, *** p<0.0005, ** p<0.005, and * p<0.05.  
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Figure 2.8: Pamidronate did not further increase osteocyte lacunar area during pregnancy. A) 
Panels show the location of measurements and representative images of lacunae from PBS and 
PAM treated dams. B) Pregnancy induced osteocytic lacunar enlargement in the femur as 
measured by backscatter electron microscopy. By the end of lactation, osteocyte lacunar area 
remodeled back to baseline. Results of One-Way ANOVA factors: PAM and (PBS) compared to 
virgin controls: ++++ p<0.00005, +++ p<0.0005, ++ p<0.005, and + p<0.05. Results of Two-Way 
ANOVA factors: **** p<0.00005, *** p<0.0005, ** p<0.005, and * p<0.05.  
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Chapter 3 Low Dose of Bisphosphonate Enhances Sclerostin Antibody-Induced Trabecular 
Bone Mass Gains in Brtl/+ Osteogenesis Imperfecta Mouse Model 
 
Introduction  
Osteogenesis imperfecta (OI) is a genetic bone disorder caused by collagen-related mutation 
resulting in type dependent skeletal phenotypes ranging from subclinical to lethal severity. [4] 
Though these phenotypes are type-dependent, OI is most commonly associated with low bone 
mass, altered bone quality, and imbalanced bone remodeling leading to skeletal fractures and 
deformities such as scoliosis, short stature, and bowing of the long bones [163]. In the presence of 
OI, upregulation of osteoclast activity causes a cellular imbalance that favors resorption, resulting 
in thinner bones with fewer trabeculae, both of which greatly increase fracture risk during 
childhood. [164] 
Despite no current cure for the disease, treatments for pediatric OI have focused on improving 
bone density to promote functional strength and consequently reduce bone fragility.  Currently, 
antiresorptive agents from the class of bisphosphonates (BPs) are the standard of care for pediatric 
OI. Through their high affinity for calcium ions, these potent inhibitors of bone resorption strongly 
bind to hydroxyapatite bone surfaces where they can later be internalized by osteoclasts to interrupt 
the resorption process. [165] Several controlled clinical trials have established the beneficial 
effects of treating pediatric OI with BP, including decreased bone turnover and increased bone 
mineral density, particularly at sites of trabecular bone. [22, 32, 166-170] During endochondral 
growth, primary trabeculae are remodeled and converted to secondary spongiosa, and extended 
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BP treatment interrupts this process, thus retaining calcified cartilage and increasing metaphyseal 
mass. In support of these studies, we and others have shown that with BP treatment, significant 
improvements in trabecular number, but not trabecular thickness are realized. [28, 96, 171-174] 
However, there remain concerns about the long-term treatment and retention of BPs in a growing 
skeleton, [175] and there remains a clinical need for additional therapeutic strategies that can 
minimize BP dose while maximizing therapeutic benefit.  
Recently, sclerostin antibody (SclAb) has gained interest as an anabolic approach for the treatment 
of OI. [47, 48, 50, 53, 176, 177] Sclerostin, expressed in mature osteocytes, inhibits bone formation 
by exerting antagonistic effects on Wnt signaling and downstream osteoblast activity. [178] We 
have previously shown a significant anabolic response to SclAb in an OI mouse model. [47, 48, 
50, 53, 176] These studies showed that treatment with a neutralizing antibody to sclerostin 
stimulated bone formation in cortical and trabecular bone, resulting in significant improvements 
in biomechanical properties. Unlike BPs, SclAb led to significant improvements in trabecular 
thickness. In the present study we sought to determine whether BPs could be used to augment 
SclAb efficacy by inducing retention of primary trabeculae, which could then serve as a substrate 
for the anabolic actions of SclAb to increase trabecular bone mass. We hypothesized that when 
combined, these two interventions would independently target different pathways of the bone 
remodeling cycle, leading to increases in trabecular bone mass greater than when either therapy 
was given alone. To accomplish this, in the present study, we test the immediate and long-term 
effects of treating rapidly growing Brtl/+ mice, harboring an OI-causing defect, with SclAb and 
BP together during growth. Our knock-in mouse model reproduces features of moderately severe 
Type IV OI. Treatment of Brtl/+ with alendronate alone increased trabecular bone mass through 
retention of calcified cartilage, with modest cortical gains that did not translate directly to 
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biomechanical improvements. [174] Conversely, treatment of Brtl/+ with SclAb alone elicited 
significant gains in both trabecular and cortical bone mass. [47] In the present study, through 
combination therapy, SclAb and BP induce gains in both trabecular thickness and number, leading 
to synergistic gains in trabecular bone stiffness, suggesting a distinct advantage to combination 
therapy in a growing mouse model of OI. 
 
Materials and Methods 
Animals 
Wild-type (WT) and Brtl/+ mice with a mixed background of SV129/CD-1/C57BL/6S were 
derived from heterozygous Brtl/+ and WT parental strains. [64] To assess the short-term effects of 
pamidronate (PAM) and SclAb combined, at 21 days of age, male WT and Brtl/+ mice received a 
single intraperitoneal injection of PAM at either 0.3 mg/kg or 0.625 mg/kg (Sigma-Aldrich, St. 
Louis, MO, USA) or saline control. These doses of PAM represent 10% and 20% of doses shown 
to induce trabecular retention for 20 days in mice of similar age. [96] After a 3-day latency period, 
mice were randomly assigned to SclAb treatment (Scl-Ab VI, 25 mg/kg; Amgen, Thousand Oaks, 
CA, USA) or saline groups and injected subcutaneously twice a week for 2 weeks (through day 
34). SclAb was chosen at a dose that consistently induced an anabolic effect in our prior studies. 
[47, 48, 50, 53, 176] Calcein and alizarin were administered 1 day before PAM and at day 35, 
respectively, by intraperitoneal injection (30 mg/kg; Sigma-Aldrich, St. Louis, MO, USA) to 
visualize the growth pattern during treatment. Short-term treatment mice (n = 7/group) were 
euthanized at day 37. Similarly, to evaluate the long-term effects of PAM and SclAb combined, 
male WT and Brtl/+ mice received two cycles of combination therapy, repeating the treatment 
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described above on day 38. Calcein, alizarin, and calcein were administered 1 day before cycle 1, 
1 day before cycle 2, and at day 53, respectively, by intraperitoneal injection (30 mg/kg). Mice (n 
= 10/group) were euthanized at day 55. A summary of the experimental design for short-term and 
long-term assessment of combination therapy is shown in Figure 3.1A, and Figure 3.1B 
respectively. A schematic of our proposed mechanism of action for combination therapy is shown 
in Figure 3.1F. All protocols and procedures were approved by the University of Michigan’s 
Committee on Use and Care of Animals. 
Micro–computed tomography 
To determine the short and long-term effects of PAM and SclAb on trabecular and cortical bone 
morphology, L5 vertebrae and left femurs were scanned in water via micro–computed tomography 
(mCT) (eXplore Locus SP; GE Healthcare Pre-Clinical Imaging, London, ON, Canada). Scans 
were performed with the source set at 80 kVp and 80 µA using the Parker method of rotation (180 
degrees plus a 20-degree fan angle), 0.5-degree increment angle, four frames averaged, and an 
acrylic beam flattener with a 0.02 Al filter were used for filtration of beam hardening artifacts. 
Images were reconstructed at a voxel size of 18 µm, and a hydroxyapatite-mimicking phantom 
was used to calibrate grayscale values for densitometry. [179]  
Treatment of the growing skeleton with antiresorptive agents induces formation of a BP-laden 
band reflecting retention of primary spongiosa in the femur. [180, 181] To study the short-term 
combined influence of PAM and SclAb on the femur, a 0.7-mm ROI was placed at this BP-induced 
retention region of the distal femur. A second ROI was located distal to the band (closer to the 
growth plate), representing bone formed subsequent to BP injection, during SclAb treatment. A 
third ROI was located proximal to the band representing a site of trabecular bone formed prior to 
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BP injection, but still under the influence of SclAb. A summary of the position of these ROIs are 
shown in Figure 3.1C. Segmentation and binarization of trabecular bone at these sites was 
performed using a local threshold adjusted at each site for optimal representation of trabecular 
microarchitecture. Trabecular bone at and distal to BP band was segmented at 1500 Hounsfield 
units (HU), while trabecular bone found at the region proximal to BP band was segmented at 1300 
HU.  
To understand the resulting effects from concurrent cycles of combination therapy in the femur, a 
5-mm ROI was placed at the metaphysis just proximal to the growth plate and extending through 
to the location of the proximal-most band of retained trabecular bone. To isolate the effects of each 
administered cyclic treatment, this full cycle ROI was broken down into representative regions of 
cycle 1 (2.7 mm) and cycle 2 (1.8 mm). Cycle 1 spanned from above the first BP band to right 
above the second induced BP band. Cycle 2 spanned above the second sclerotic BP band to right 
above the growth plate. A schematic of the placement of these three ROIs is shown in Figure 3.1D. 
Due to the maturity of the bone and size of ROIs, a local auto-threshold was used to quantify 
trabecular bone at these three regions. [182]  
Although a retention-related band was observed in the femur following BP treatment, a “bone in 
bone” appearance was induced in the vertebral body, consistent with vertebral growth patterns and 
clinical observations. [183] As a result, an ROI was placed between the cranial and caudal 
endplates of the L5 vertebrae to analyze both short-term and long-term effects of combination 
treatment (Figure 3.1E). Vertebral cortical and trabecular bone were separated through manual 
contouring to denote the outer and inner boundaries of the cortex and segmented by a local auto-
threshold.  
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To measure both short-term and long-term effects of treatment on femoral cortical bone, an ROI 
spanning 15% of total femoral length was centered midway between the lateral third trochanter 
and the distal femoral growth plate in all samples. A local auto- threshold was used to quantify 
cortical bone. Bone architecture parameters (trabecular number [Tb.N], trabecular thickness 
[Tb.Th], bone volume fraction [BV/TV], and cortical thickness [C.Th]) were analyzed using 
commercially available software (MicroView Advanced Bone Analysis Application; GE 
Healthcare Pre-Clinical Imaging, London, ON, Canada). 
Bone histomorphometry 
To qualitatively analyze bone formation response from short-term and long-term combination 
therapy, femurs and L2 vertebrae were embedded without decalcification in methyl methacrylate. 
Both tissues were sectioned longitudinally with a Reichert-Jung Polycut microtome (Reichert-
Jung, Heidelburg, Germany) at a thickness of 8 µm and mounted on gelatin-coated glass slides. 
An upright microscope (Nikon Eclipse Ni-U, Tokyo, Japan) associated with a DS-Fi2 digital 
camera and NIS BR software (Nikon, Champigny-sur-Marne, France) was used to acquire calcein 
and alizarin fluorescent images with a 10x dry objective. 
Biomechanical testing 
To assess the mechanical effects of short-term and long-term combination therapy, L5 vertebrae 
(short-term and long-term) and left femurs (long-term only) were loaded to failure in compression 
and four-point bending, respectively, using an MTS 858 Mini-Bionix servo-hydraulic testing 
system (MTS Systems Corp., Eden Prairie, MN, USA). All specimens were kept hydrated in 
lactated Ringer’s solution (LRS) prior to mechanical testing. The vertebral body was vertically 
aligned along its loading axis with an alignment pin (attached to lower platen and extending 
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through the spinal column) and compressed to failure at a displacement rate of 0.05 mm/s. For 
four-point bending, the posterior surface of the femur was oriented in tension and the mid-
diaphysis was loaded to failure at a displacement rate of 0.5 mm/s. Force and vertical 
displacements were continuously recorded throughout each test by a 50-lb load cell (Sensotec, 
Columbus, OH, USA) and an external linear variable differential transducer (LVDT; Lucas 
Schavitts, Hampton, VA, USA), respectively. A custom-developed LABVIEW program was used 
to calculate the mechanical properties for both tissues. 
Statistics 
Regional variations in bone architecture and biomechanics among the different treatments were 
determined using two-way ANOVA (GraphPad Prism 6.0; GraphPad Software, Inc., La Jolla, CA, 
USA) for each genotype independently. Values of p<0.05 were considered significant, and 
significance is expressed on each plot for independent effects of PAM (vertical arrow) and SclAb 
(horizontal arrow) within each genotype. Data are reported through dumbbell dot plots that display 
group means of PAM treatment (white markers) and PAM + SclAb treatment (solid markers) for 
both Brtl/+ (blue and circles) and WT (black and squares). Standard deviations are shown as 
shadows behind each marker. 
 
Results 
PAM and SclAb contribute distinct gains in distal femoral trabecular number and thickness 
following a single cycle of combination therapy 
At the metaphyseal band site, where BP induces the greatest trabecular retention, PAM 
monotherapy induced a significant dose-dependent preservation of Tb.N at 0.3 mg/kg (Brtl/+ 3.297 
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± 1.796/mm; WT 5.677 ± 1.446/mm) and 0.625 mg/kg (Brtl/+ 4.648 ± 1.471/mm; WT 6.225 ± 
1.675/mm) compared to vehicle treated control (Brtl/+ 1.905 ± 0.746/mm; WT 3.343 ± 0.574/mm; 
Figure 3.2, Table 3.1). Although PAM solely acted to stabilize Tb.N, SclAb monotherapy induced 
significant gains in both Tb.Th (Brtl/+ 0.049 ± 0.004 mm; WT 0.059 ± 0.007 mm) and Tb.N (Brtl/+ 
3.143 ± 0.574 mm; WT 5.272 ± 1.349 mm) compared to untreated control (Brtl/+ 0.035 ± 0.005 
mm, 1.905 ± 0.746/mm; WT 0.037 ± 0.003 mm, 3.343 ± 0.574/mm). When PAM and SclAb were 
administered together, PAM continued to show no effect on Tb.Th, while SclAb triggered 
consistent thickness gains of 0.049 ± 0.008 mm for Brtl/+ and 0.067 ± 0.013 mm for WT across 
PAM doses. Interestingly, SclAb alone induced retention of Tb.N comparable to that of 0.3 mg/kg 
PAM alone (3.143 ± 1.133/mm versus 3.297 ± 1.796/mm). Together, combining SclAb and PAM 
during a single cycle of combination therapy contributed to a maximum increase in bone volume 
fraction of 0.263 ± 0.069 for Brtl/+ and 0.443 ± 0.130 for WT over untreated control (Brtl/+ 0.065 
± 0.027; WT 0.124 ± 0.025). Comparing regions proximal and distal to metaphyseal band, we 
noted that these effects were isolated to the site of concurrent drug administration (see Figure 3.3 
and Table 3.2). Trabecular bone distal to BP site showed minimal effect of BP as Tb.N was not 
significantly different from placebo. However, SclAb induced consistent gains in Tb.Th and Tb.N 
as monotherapy. At the proximal-most sites formed prior to BP intervention, BP effect was less 
evident, while significant gains in Tb.Th and BV/TV were still observed with SclAb.  
Multiple cycles help stabilize bone mass gains from combination treatment  
Following two cycles of combination therapy (Figure 3.4A, Table 3.3), in trabecular regions 
extending across the entire metaphysis, PAM continued to show no effect on Tb.Th, acting solely 
to further stabilize Tb.N at 0.3 mg/kg (Brtl/+ 3.813 ± 0.856/mm; WT 4.557 ± 0.624/mm) and 0.625 
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mg/kg (Brtl/+ 4.329 ± 0.863/mm; WT 5.128 ± 0.687/mm) compared to untreated controls (Brtl/+ 
2.929 ± 0.753/mm; WT 4.318 ± 1.131/mm). SclAb continued to induce gains in Tb.Th (Brtl/+ 
0.050 ± 0.004 mm; WT 0.057 ± 0.006 mm), as well as a significant preservation of Tb.N (Brtl/+ 
4.899 ± 0.595/mm; WT 5.796 ± 0.823/mm) across all PAM doses. As a result of these effects, 
maximum gains in bone volume fraction of 0.262 ± 0.057 for Brtl/+ and 0.362 ± 0.071 for WT 
were observed due to cumulative effects from both drugs compared to untreated control (Brtl/+ 
0.107 ± 0.039; WT 0.189 ± 0.067). To further explore the effect of dose and time, the entire 
metaphyseal trabecular bone ROI was subdivided into two separate proximal and distal regions. 
The proximal-most region represented cycle 1 (Figure 3.4B, Table 3.3), and represents the fate of 
the band explored in Figure 3.2 following a second cycle of therapy. During a typical course of 
therapy, BP will interfere with the growth-associated trabecular modeling that would normally 
cause trabeculae to gradually disappear during growth, thus stabilizing trabecular number over 
time. Here (Figure 3.4B, Table 3.3), Tb.N of PAM-alone animals drops below levels shown in 
Figure 3.2, confirming that the low dose of PAM was insufficient to stabilize bone mass long-
term. Although the low dose of PAM was sufficient to restore Brtl/+ Tb.N to WT levels after the 
first cycle, the higher dose was required for the rescue effects to sustain throughout the second 
cycle. The distal-most region chosen represented cycle 2 (Figure 3.4C, Table 3.3), and shows the 
retention band induced by the second PAM administration in the presence or absence of SclAb. 
Here, progressive gains in Tb.N are apparent, and Tb.Th gains in response to SclAb following 
cycle 2 (Brtl/+ 29%; WT 28%) were substantially less than those observed in the proximal region 
of interest (Brtl/+ 53%; WT 53%), reflecting either the shorter treatment duration for this site, or 
a saturation effect of SclAb on trabecular thickness.  
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Multiple treatments of PAM and SclAb significantly slows the turnover of primary spongiosa 
To assess the fate of bone formed during a single treatment cycle (Figure 3.5A), calcein (green) 
was administered at the beginning of PAM (or control) and alizarin (red) at the end of SclAb (or 
control) treatment. Using this labeling scheme, bone formed and retained following PAM is shown 
in green, while bone formed subsequent to PAM is green. During growth, untreated Brtl/+ control 
showed a significant loss of primary trabeculae, reflected by total absence of green trabecular label 
(Figure 3.5A, top left). PAM alone increased preservation of trabecular bone shown by retained 
spicules of calcein label (Figure 3.5A, top right). In contrast SclAb alone (Figure 3.5A, bottom 
left) exhibited retention of calcein label with adjacent alizarin-labeled bone, indicating trabecular 
thickening on preserved primary spongiosa. Combined, SclAb and PAM induced an additive bone 
mass response at the site of concurrent drug administration (Figure 3.5A, bottom right). These 
patterns of trabecular preservation and thickening amplify under the influence of two cycles of 
therapy (Figure 3.5B) as gains expand further down the proximal femur compared to gains seen 
after one cycle (Figure 3.5A). Significant preservation of second-cycle Tb.N is apparent from 
alizarin-labeled trabeculae in PAM-treated femurs (Figure 3.5B, top right), whereas SclAb alone 
led to both retention of trabeculae and thickening, indicated by alizarin-labeled trabeculae with 
abundant calcein label (Figure 3.5B, bottom left). Robust gains in trabeculae and thickness are 
appreciated when both drugs were given together in multiple cycles as seen through retained 
alizarin-labeled trabeculae with a calcein-labeled thickness (Figure 3.5B, bottom right). 
Multiple cycles of combination therapy induce synergistic gains in vertebral trabecular bone 
mass 
Microstructural analysis of the lumbar vertebra demonstrated similar findings, albeit to a lesser 
extent, as seen in the femoral metaphysis, confirming consistency of effects at axial and 
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appendicular sites. Under the influence of a single treatment cycle (Figure 3.6A, Table 3.4), PAM 
monotherapy significantly stabilized Tb.N at 0.3 mg/kg (Brtl/+ 6.137 ± 0.536/mm; WT 6.573 ± 
0.459/mm) and 0.625 mg/kg (Brtl/+ 6.376 ± 0.569/mm; WT 6.886 ± 0.363/mm) over placebo 
control (Brtl/+ 5.787 ± 0.300/mm; WT 6.130 ± 0.271/mm), with no effect on Tb.Th. SclAb 
monotherapy produced gains in both Tb.N (Brtl/+ 6.208 ± 0.420/mm; WT 6.816 ± 0.376/mm) and 
Tb.Th (Brtl/+ 0.046 ± 0.002 mm; WT 0.053 ± 0.004 mm). As found in the femur, when SclAb 
was administered with PAM, little additional gains were observed in Tb.N. Higher doses of PAM 
were required to see additional trabecular thickening in Brtl/+, while WT showed an average 0.055 
mm increase in Tb.Th with the two drugs combined. Despite these observations during a single 
cycle of combination therapy, overall gains in BV/TV were comparable whether drugs were given 
combined (Brtl/+ 0.298 ± 0.043; WT 0.388 ± 0.029) or SclAb alone (Brtl/+ 0.289 ± 0.032; WT 
0.365 ± 0.040). Lumbar vertebrae benefited strongly from two treatment cycles (Figure 3.6B), 
triggering a maximum synergistic response on BV/TV (Brtl/+ 0.421 ± 0.053; WT 0.504 ± 0.053) 
over placebo (Brtl/+ 0.235 ± 0.026; WT 0.293 ± 0.037) compared to 0.625 mg/kg PAM (Brtl/+ 
0.275 ± 0.046; WT 0.315 ± 0.033) and SclAb (Brtl/+ 0.339 ± 0.043; WT 0.452 ± 0.065) 
monotherapy. PAM continued to increase bone mass through Tb.N at 0.3 mg/kg (Brtl/+ 6.002 ± 
0.444/mm; WT 6.487 ± 0.346/mm) and at 0.625 mg/kg (Brtl/+ 6.300 ± 0.614/mm; WT 6.838 ± 
0.340/mm) with no effect on Tb.Th. SclAb induced strong gains in both Tb.N (Brtl/+ 6.867/mm; 
WT 6.889/mm) and Tb.Th (Brtl/+ 0.058 ± 0.004 mm; WT 0.070 ± 0.007 mm) across all PAM 
dosages, contributing substantially to the overall synergistic gains in lumbar vertebrae trabecular 
bone mass.   
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Substantial preservation of Tb.N and increased Tb.Th in vertebral body 
To evaluate the response of newly formed bone under the effects of a single treatment cycle (Figure 
3.7A), calcein (green) was administered prior to PAM treatment and alizarin (red) after SclAb 
treatment. Brtl/+ control showed few primary trabeculae labeled with calcein, which was stabilized 
with a single dose of PAM. SclAb showed preservation of calcein labeled bone with alizarin 
labeled perimeters suggesting trabecular thickening. These observations confirm the antiresorptive 
and anabolic effects of both treatments, which led to further additive gains in bone mass. Newly 
formed bone under the effects of multiple treatment cycles (Figure 3.7B), was labeled with calcein 
(green) at the beginning of treatment, alizarin (red) between cyclic treatments and again with 
calcein (green) at the end of treatment. Labeling of control samples showed considerable loss of 
primary trabeculae. PAM alone promoted the retention of primary trabeculae, noted by 
considerable alizarin-labeled bone adjacent to the growth plates. SclAb alone triggered both 
trabecular retention and thickness gains. Combination of both drugs administered cyclically 
induced a robust trabecular response which extended to the periosteal bone surface. 
PAM intervention does not interfere with SclAb ability to improve femoral rigidity 
PAM effects were isolated to the lumbar vertebrae and femoral trabecular bone, with no apparent 
effects on femoral diaphyseal cortical bone structure or biomechanical properties. Rather, gains in 
cortical thickness were solely attributed to SclAb because our administered PAM treatment used 
doses significantly lower than those used in human studies. After a single cycle of combination 
therapy (Figure 3.8A, Table 3.5), SclAb monotherapy induced greater gains in femoral C.Th 
(Brtl/+ 0.182 ± 0.008 mm; WT 0.234 ± 0.009 mm) than when combined with 0.3 mg/kg PAM 
(Brtl/+ 0.171 ± 0.017 mm; WT 0.234 ± 0.009mm) or 0.625 mg/kg PAM (Brtl/+ 0.176 ± 0.012 
mm; WT 0.216 ± 0.028mm) compared to placebo (Brtl/+ 0.152 ± 0.016 mm; WT 0.192 ± 0.022 
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mm). However, this effect was transient, because after two cycles (Figure 3.8B), consistent C.Th 
gains of 0.231 ± 0.023 mm in Brtl/+ and 0.277 ± 0.023 mm in WT were observed across all PAM 
doses. As a result of these C.Th changes, SclAb consistently improved femoral rigidity through 
gains in stiffness (Brtl/+ 231.768 ± 44.278N/mm; WT 272.632 ± 57.425N/mm) and ultimate load 
(Brtl/+ 35.379 ± 6.741 N; WT 47.816 ± 9.937 N) across all PAM doses, driven by gains in bending 
moment (Brtl/+ 0.158 ± 0.045 mm4; WT 0.207 ± 0.028 mm4) and cross-sectional area (Brtl/+ 1.919 
± 0.200 mm2; WT 2.234 ± 0.267mm2) as seen in Figure 3.8C.  
PAM and SclAb synergistically improve Brtl/+ vertebral stiffness over monotherapy effects  
Similar to the cortical effects seen in the femur, C.Th gains in the vertebral body were influenced 
by SclAb, not PAM. A single cycle of combination therapy (Figure 3.9A, Table 3.6) resulted in 
lower gains in C.Th at 0.3 mg/kg (Brtl/+ 0.086 ± 0.007 mm; WT 0.102 ± 0.006 mm) and 0.625 
mg/kg (Brtl/+ 0.088 ± 0.007 mm; WT 0.102 ± 0.007 mm) than SclAb monotherapy (Brtl/+ 0.091 
± 0.005 mm; WT 0.100 ± 0.005 mm). However, with multiple cycles (Figure 3.9B), greater gains 
in C.Th were achieved at 0.3 mg/kg (Brtl/+ 0.090 ± 0.006 mm; WT 0.103 ± 0.010 mm) and 0.625 
mg/kg (Brtl/+ 0.093 ± 0.009 mm; WT 0.106 ± 0.008 mm). Functionally, over a single cycle of 
therapy (Figure 3.9C), PAM dose-dependently improved vertebral stiffness and SclAb amplified 
this response (Brtl/+ 29%, WT 32%). Improvements in ultimate load were attributed to SclAb with 
gains of 48% in Brtl/+ and 58% in WT. Over two cycles of combination treatment (Figure 3.9D), 
maximum gains in vertebral stiffness were observed when both PAM (Brtl/+ 75.650 ± 8.031 
N/mm; WT 119.729 ± 24.514 N/mm) and SclAb (Brtl/+ 81.307 ± 15.531 N/mm; WT 136.688 ± 
16.367 N/mm) were administered alone. When administered together in sequential cycles, WT 
showed maximum additive gains (156.340 ± 28.962 N/mm) compared to each treatment alone. 
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Remarkably, a synergistic response was observed in Brtl/+, with a maximum stiffness increase of 
130.945 ± 25.920 N/mm compared to placebo control (46.974 ± 20.181 N/mm). 
 
Discussion 
The results in this study show Brtl/+ mice with a genetic knock-in for moderately severe Type IV 
OI responded favorably to repeated cycles of a single dose of antiresorptive PAM in combination 
with anabolic SclAb. The immediate effects of this combination therapy showed that both 
interventions stimulated gains in bone mass through different means, leading to overall 
improvements in biomechanical function. Although a preservation of Tb.N was observed through 
PAM, SclAb led to gains in both Tb.N and Tb.Th, as well as a significant cortical bone response. 
When this combination therapy was administered twice cyclically, the resulting gains in trabecular 
bone mass were dependent on anatomic site; cumulative for long bones and synergistic for the 
vertebral body. These findings may have a strong clinical utility to increase bone mass in OI 
patients—particularly those with excessive high bone turnover leading to severe trabecular 
osteopenia that might make them more resistant to anabolic therapy alone.  
Antiresorptive BPs continue to be the most common intervention used in pediatric OI. Numerous 
studies have shown a favorable bone response to BP therapy in both preclinical studies using OI 
mouse models [24, 28, 174, 184] and clinical studies of children with OI. [20, 22, 24-26, 167, 185] 
By their antiresorptive activity, BPs have been proposed to decrease the high bone turnover 
characteristic of OI, increase metaphyseal bone mass by increasing trabecular number, and 
increase cortical bone mass by inhibiting endosteal resorption. However, concern for long half-
life,[186] microdamage accumulation,[187] and delayed healing [188] have led to attempts to 
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minimize treatment dose. [175] Recently, SclAb has gained interest as a promising anabolic 
approach for the treatment of OI. In contrast to BP, SclAb has been shown to increase trabecular 
bone mass in OI models through trabecular thickening, and increase cortical bone mass through 
periosteal apposition. [47, 48, 50] Furthermore, in a growing model, periosteal apposition will 
occur as a result of growth, which contributes to further bone mass gains because PAM has not 
been shown to affect non-remodeling surfaces. Therefore, we hypothesized that a combination of 
these two agents may lead to additive if not synergistic structural and functional gains. When given 
together, we observed that BPs induce retention of primary trabeculae, which can serve as a 
substrate for the subsequent anabolic response of SclAb, whereas cortical bone mass gains resulted 
from SclAb alone.  
Combination effects have been explored with BP following SclAb in order to preserve gains in 
bone mass following cessation of drug clinically [189] and in OI models. [53] Alternatively, SclAb 
following BP has been explored using ovariectomized rats in which SclAb induced gains in bone 
mass regardless of prior BP exposure. [190] This study was performed in aged, osteoporotic rats, 
which have considerably different growth plate dynamics than in the present study. In another OI 
mouse model, SclAb was combined with zoledronic acid,[95] where no synergistic effects were 
observed. Rather, the treatment effect from zoledronic acid alone led to >300% gains in proximal 
tibial trabecular bone volume fraction, with no additional gains observed when zoledronic acid 
was combined with SclAb. In the present combination study, we likely avoided this saturation 
response with lower doses of BP, triggering more modest trabecular preservation, allowing SclAb 
to synergistically increase bone mass by increasing trabecular thickness.  
The present study differs from these other combination therapy studies because we aimed to 
explore low doses of PAM which, if given alone, would be insufficient to generate long-term 
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preservation of trabecular bone. Indeed, when tracking the fate of the trabecular bone generated 
by the first cycle of PAM, we observed a lack of long-term antiresorptive effects, particularly in 
the vertebrae. Yet when administered together with SclAb, both drugs combined led to cumulative 
gains on bone mass. At the site of concurrent treatment, PAM induced a sclerotic metaphyseal 
band consistent with previous observations of BP treatment stabilizing primary spongiosa near the 
growth plate. [191] Treatment with PAM alone showed a significant effect on bone volume 
fraction for both Brtl/+ and WT when compared to untreated controls, solely due to a significant 
dose-dependent preservation of Tb.N with no concurrent effect on Tb.Th. Similar gains in bone 
volume were triggered with SclAb monotherapy; however, these were attributed to an effect on 
both Tb.N and Tb.Th. Gains in Tb.Th likely resulted from a direct anabolic effect on existing 
trabecular bone. However, gains in Tb.N could have resulted from either stabilization of thin 
trabeculae destined for remodeling via increased bone formation on those surfaces, or through a 
mild antiresorptive effect, because SclAb has been shown to have both anabolic and anticatabolic 
actions. [192] Indeed, SclAb alone preserved Tb.N to levels equivalent to low-dose PAM, 
suggesting a similar potency of antiresorptive action between the two drugs. When given together, 
extended gains in trabecular bone mass were attributed to SclAb-induced trabecular thickening at 
sites formed following PAM exposure and retention of trabecular number. These observations 
were confirmed through histomorphometry. Observations at sites distal and proximal to the 
metaphyseal band helped verify that PAM bone response was constrained to its induced sclerotic 
band, while SclAb led to trabecular thickening away from these sites.  
The same trabecular response was observed in the vertebral body for both Brtl/+ and WT, to a 
slightly greater extent, as was observed in the femoral metaphysis. These findings are consistent 
with other BP studies that show a variable BP binding and bone density response between axial 
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versus appendicular, and cortical versus trabecular sites. [181, 193] Following two cycles of 
combination therapy, a synergistic effect on bone mass was observed in the vertebral body that 
was not observed in the femoral metaphysis, which instead showed an additive effect of the two 
interventions. Histomorphometry of two cycles of combination therapy demonstrated thickened 
bands of retained primary spongiosa emerging from both growth plates of the vertebra consistent 
observations in other pediatric BP studies. [183, 194, 195]  
In addition to trabecular effects, SclAb induced an anabolic response in femoral and vertebral 
cortical bone, because gains observed were solely attributed to SclAb, even when administered in 
combination with PAM. This increase in cortical thickness correlates with previous findings where 
growing Brtl/+ mice treated with SclAb showed cortical thickness gains in the femoral midshaft 
over a similar treatment duration. [47] Furthermore, progressive gains in cortical thickness were 
observed comparing one versus two cycles of SclAb monotherapy. Although clinical studies of 
children with OI have shown slight changes in cortical bone from PAM treatment, [174, 196-198] 
in the present study, PAM had no effect on cortical thickness, likely due to the low treatment 
duration and doses used in the present study compared to those in clinical trials. Low doses of 
PAM were deliberately chosen for this study in order to minimize the antiresorptive effect and not 
mask the potential combination effects hypothesized from both drugs together.  
Two cycles of PAM monotherapy showed no effect on femoral stiffness or load in either Brtl/+ 
and WT. SclAb, on the other hand, improved both stiffness and load as a result of the strong 
anabolic effect on cortical bone. When both drugs were administered concurrently, SclAb 
continued to be the sole contributor to these improvements in whole-bone mechanical properties. 
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Similarly, in the vertebral body, Brtl/+ ultimate load was only improved by SclAb, yet both PAM 
and SclAb led to strong gains in vertebral stiffness. In fact, following two cycles of combined 
treatment, Brtl/+ stiffness improved synergistically when compared to combined effects from 
monotherapy of either drug. This finding may have important implications for treatment of spinal 
deformities in OI. Deformation of the spine arises from both anatomical and functional factors 
resulting from the OI phenotype. Depending on the severity of the deformity or fracture frequency, 
prophylactic interventions like BP treatment can potentially reduce fracture incidence. Combining 
SclAb with PAM stabilized vertebral trabecular bone resulting in significant gains in vertebral 
stiffness. SclAb alone improved maximum load, likely due to additional gains in cortical thickness 
that were not evident following PAM. These findings confirm other studies that have shown that 
C.Th is a primary determinant feature for compressive strength of the whole vertebral body. [199-
201] 
This study has several limitations. Because OI is a disease of many mutations, the results of this 
study may not extend to all types of OI. Additionally, the Brtl/+ mouse fragility phenotype is of 
moderate severity, and the mouse does not suffer spontaneous fractures. In addition, the study was 
only performed in male mice and it is now well established that gender can affect the outcome of 
drug treatments. Furthermore, BP action when given after closure of the growth plate during 
skeletal maturity will not yield the same findings as observed in this study because turnover of 
primary spongiosa will be nonexistent. In many of our outcomes, treatment with our lowest PAM 
dose alone improved bone mass to WT control levels, effectively rescuing the phenotype, while 
our higher PAM dose induced gains in bone mass greater than WT baseline. Although our goal 
was not to directly titrate our treatment outcomes to match untreated WT levels, we believe that 
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further adjustment of treatment doses and/or duration will vary depending on clinical severity to 
best represent a “rescue” response.  
SclAb has been proposed as a novel anabolic intervention to treat the low bone mass and fragility 
phenotype present in patients with OI. The results in this study extend our previous observations 
of single-drug therapy in Brtl/+ [47, 174] and show the benefits of combining SclAb with 
antiresorptive treatment during growth. In severe cases of OI, where extreme low bone mass may 
result from excessive resorption of primary trabeculae during endochondral growth, SclAb alone 
might not be enough to significantly improve trabecular bone volume because of lack of bone upon 
which to exert an anabolic action. Thus, in cases of extreme low bone mass, concurrent 
antiresorptive and anabolic therapy might further improve bone formation outcomes. Importantly, 
these results suggest that modest doses of BP, which would otherwise not induce a sustained 
therapeutic effect, may be sufficient to preserve trabecular architecture enough to permit an 
anabolic action of SclAb on bone which would otherwise be remodeled. Together, these preclinical 
results support the scientific premise that antiresorptive and anabolic combination therapy during 
early stages of skeletal growth can help induce greater gains in bone mass in OI than either drug 
alone. The present data provides key preclinical results to support a treatment plan to maximize 
combination therapy in OI, or other diseases associated with low bone mass during pediatric 
growth and development. 
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Figures 
 
Figure 3.1: Schematic of short and long-term treatment timelines and ROI placement. 
Combination therapy to assess the effects after (A) a single cycle and (B) concurrent cycles of 
combination therapy. Region of interest placement in distal femoral metaphysis to analyze the (C) 
short-term, (D) long-term, and (E) vertebral trabecular bone effects of combination therapy. (F) 
Proposed mechanism of action for combination therapy.  
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Figure 3.2: Trabecular response at the femur following single cycle of combination therapy. µCT 
analysis at the site of concurrent drug administration showed that PAM induced a significant dose-
dependent increase in Tb.N whereas SclAb contributed to significant gains in both Tb.N and 
Tb.Th. Together these independent gains led to an additive gain in bone volume fraction with 
increasing PAM doses. Results of two-way ANOVA factors: *p<0.05; **p<0.01; ***p<0.001; 
****p<0.0001.  
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Figure 3.3: Isolated effects proximal and distal to site of concurrent drug administration. A) Sites 
of bone formed following PAM cessation showed that gains in bone volume fraction were 
attributed solely to SclAb-induced trabecular thickening, with an average increase of 40% for 
Brtl/+ and 55% for WT across PAM doses. Gains in TbN were attributed solely to SclAb, not 
PAM, reflecting treatment site specificity and a mild anti-resorptive effect of the drug. B) Region 
proximal to metaphyseal band, representing trabecular bone formed prior to BP injection but under 
the influence of SclAb, showed a significant effect on bone volume primarily due to an average 
trabecular thickening of 21% for Brtl/+ and 40% for WT.  
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Figure 3.4: Trabecular response at the femur following two cycles of combination therapy.  (A) 
Entire metaphyseal trabecular bone ROI following two cycles of combination therapy showed that 
PAM continued to influence Tb.N while inducing no effects on Tb.Th. SclAb, however, induced 
gains in both Tb.Th and Tb.N. Each cyclic treatment was separately analyzed by subdividing the 
entire metaphyseal trabecular bone ROI into (B) cycle 1 and (C) cycle 2. Isolating the effects of 
each administered cycle confirmed that these low doses of PAM were weak in sustaining long-
term trabeculae preservation. Results of two-way ANOVA factors: *p<0.05; **p<0.01; 
***p<0.001; ****p<0.0001.  
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Figure 3.5: Metaphyseal bone formation activity mapped with calcein and alizarin following a 
single and concurrent cycles of combination therapy. Histological sections of Brtl/+ metaphysis 
revealed short-term (A) and long-term (B) bone formation activity from a single and concurrent 
cycles of combination therapy, respectively. (A) At the BP-induced retention region, higher 
dosages of PAM were associated with greater primary trabeculae retention (yellow), while SclAb 
predominantly increased thickness (red). (B) Consecutive cycles of combination therapy showed 
a greater robust effect on bone mass with higher dosages of PAM. Calcein (green) was 
administered at the beginning and end of concurrent treatment cycles while alizarin (red) was 
administered prior to the second cyclic treatment. Sections visualized represent n = 4 per group.  
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Figure 3.6: Trabecular response in the vertebra following single cycle of combination therapy.  
(A) Microstructural properties of the vertebral trabecular bone reveal overall preservation of Tb.N 
with PAM and increased Tb.Th with SclAb after a single cycle of combination therapy. (B) With 
multiple treatment cycles, the response on Tb.N and Tb.Th was highly amplified leading to 
synergistic gains on bone mass. Results of two-way ANOVA factors: *p<0.05; **p<0.01; 
***p<0.001; ****p<0.0001.  
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Figure 3.7: Vertebral bone formation activity mapped with calcein and alizarin following a single 
and concurrent cycles of combination therapy. Histological coronal sections of Brtl/+ revealed 
bone formation activity from a single (A) and multiple (B) cycles of combination therapy. (A) 
Under a single treatment cycle, higher dosages of PAM were associated to greater primary 
trabeculae retention (green), while SclAb predominantly increased thickness and connectivity 
between growth plates (red). (B) Multiple treatment cycles showed an evident trabecular retention 
response from both PAM and SclAb; however, SclAb also induced gains in trabecular thickness 
(green). Together a robust trabecular response was triggered leading to uniform trabecular bone 
distribution between growth plates. Sections visualized represent n = 4 per group.  
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Figure 3.8: Effects on femoral mechanical and cortical properties from a single and concurrent 
cycles of combination therapy.  (A) Femoral cortical analysis revealed SclAb influence on C.Th 
varies in the presence of PAM after a single treatment cycle. (B) Following subsequent cycles of 
combination therapy, C.Th nearly doubled solely in response to SclAb. (C) Functionally, multiple 
cycles PAM and SclAb led to additive gains in femoral stiffness and ultimate load with progressive 
PAM doses. Results of two-way ANOVA factors: *p<0.05; **p<0.01; ***p<0.001; 
****p<0.0001.  
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Figure 3.9: Effects on vertebral mechanical and cortical properties from a single and concurrent 
cycles of combination therapy.  (A) Vertebral cortical analysis revealed that after a single cycle, 
SclAb triggered greater gains in C.Th than when combined with PAM. (B) Following two cycles, 
however, consistent gains in C.Th were observed across all PAM dosages. (C) Functionally, 
following a single combination cycle, PAM effect on trabecular preservation helped improve 
vertebral stiffness while SclAb amplified these effects. Significant improvements in ultimate load 
were solely attributed to SclAb. (D) Both drugs improved ultimate load through an additive 
response, however, induced a synergistic effect on vertebral stiffness following multiple cycles of 
combination treatment. Results of two-way ANOVA factors: *p<0.05; **p<0.01; ***p<0.001; 
****p<0.0001.  
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Tables 
 
Table 3.1: Trabecular response at the femur following single cycle of combination therapy. MicroCT analysis at the site of concurrent 
drug administration showed that PAM induced a significant dose-dependent increase in TbN while SclAb contributed to significant 
gains in both TbN and TbTh. Together these independent gains led to an additive gain in bone volume fraction with increasing PAM 
doses. The mean and standard deviation (mean ± SD) of each bone parameter is reported.  
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Table 3.2: Isolated effects proximal and distal to site of concurrent drug administration. MicroCT analysis of sites of bone formed 
following PAM cessation showed that gains in bone volume fraction were attributed solely to SclAb-induced trabecular thickening 
across all PAM dosages. Gains in TbN were attributed solely to SclAb, not PAM, reflecting treatment site specificity and a mild anti-
resorptive effect of the drug. Region proximal to metaphyseal band, representing trabecular bone formed prior to BP injection but under 
the influence of SclAb, showed a significant effect on bone volume primarily due to an average trabecular thickening.  
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Table 3.3: Trabecular response at the femur following two cycles of combination therapy Entire metaphyseal trabecular bone ROI 
following two cycles of combination therapy showed that PAM continued to influence TbN while inducing no effects on TbTh. SclAb, 
however, induced gains in both TbTh and TbN. Each cyclic treatment was separately analyzed by subdividing the entire metaphyseal 
trabecular bone ROI into their respective cycles. Isolating the effects of each administered cycle confirmed that these low doses of PAM 
were weak in sustaining long-term trabeculae preservation. The mean and standard deviation (mean ± SD) of each bone parameter is 
reported.ion proximal to metaphyseal band, representing tracular bone formed prior to BP injection but under the influence of SclAb, 
showed a significant effect on bone volume primarily due to an average trabecular thickening.  
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Table 3.4: Trabecular response in the vertebra following single cycle of combination therapy.Microstructural properties of the vertebral 
trabecular bone reveal overall preservation of TbN with PAM and increased TbTh with SclAb after a single cycle of combination 
therapy. With multiple treatment cycles, the response on TbN and TbTh was highly amplified leading to synergistic gains on bone mass. 
The mean and standard deviation (mean ± SD) of each bone parameter is reported. 
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Table 3.5: Effects on femoral mechanical and cortical properties from a single and concurrent cycles of combination therapy. Femoral 
cortical analysis revealed SclAb influence on CTh varies in the presence of PAM after a single treatment cycle. Following subsequent 
cycles of combination therapy, CTh nearly doubled solely in response to SclAb. Functionally, multiple cycles PAM and SclAb led to 
an additive gains in femoral stiffness and ultimate load with progressive PAM doses. The mean and standard deviation (mean ± SD) of 
each bone parameter is reported.  
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Table 3.6: Effects on vertebral mechanical and cortical properties from a single and concurrent cycles of combination therapy. 
Vertebral cortical analysis revealed that after a single cycle, SclAb triggered greater gains in CTh than when combined with PAM. 
Following two cycles, however, consistent gains in CTh were observed across all PAM dosages. Functionally, following a single 
combination cycle, PAM effect on trabecular preservation helped improve vertebral stiffness while SclAb amplified these effects.  
Significant improvements in ultimate load were solely attributed to SclAb. Both drugs improved ultimate load through an additive 
response, however, induced a synergistic effect on vertebral stiffness following multiple cycles of combination treatment. The mean and 
standard deviation (mean ± SD) of each bone parameter is reported.  
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Chapter 4 Conclusions 
 
The purpose of these studies was to identify potential treatment plans that would provide the best 
clinical outcome to OI patients who require intervention during pregnancy or lactation and patients 
with severe OI. Based on the findings from these studies, the following conclusions, limitations 
and future studies are presented: 
Bisphosphonate Treatment Intervention during Pregnancy and Lactation Leads to 
Temporal Inhibition of Lactation-Induced Bone Loss on the Maternal Skeleton 
 Pregnancy-induced bone mass gains were solely attained through significant increase in 
Tb.N retention while lactation-induced bone loss were attributed to loss in both Tb.N and 
Tb.Th 
 PAM intervention amplified pregnancy-induced bone mass gains and prevented lactation-
induced bone loss when administered prior to conception (PC) 
 Temporal effects from BP treatment during pregnancy and lactation showed that PAM was 
more effective in preserving maternal bone mass when treatment was administered at early 
stages of pregnancy (E15) or lactation (D1) and no preservation was observed when treated 
at late stages of lactation (D10 or D15) 
 PAM amplified pregnancy-induced vertebral stiffness gains and induced a temporal 
conservation of femoral and vertebral stiffness when assessed following lactation  
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 No negative fetal or neonatal skeletal effects were observed in offspring from PAM treated 
dams despite preventing lactation-induced maternal bone loss 
 PAM treatment had no effect on pregnancy-induced osteocyte osteolysis 
 Greater osteoclast numbers were observed while osteoclast surface coverage remained 
unaffected with PAM treatment 
Limitations 
This study focused on assessing maternal skeletal effects following PAM administration and how 
maternal exposure may affect embryonic and neonatal bone development. In order to assess long-
term history of BP therapy, a single PAM dosage was administered prior to conception, which 
does not reflect continuous BP accumulation in the maternal skeleton due to extensive treatment 
prior to conception in humans. However, we chose this approach because BPs would be embedded 
on the surface of the maternal skeleton rather than sequestered deep within the bone matrix, thus 
making BPs more readily available for offspring to be exposed to recycled BPs secondary to 
maternal bone resorption. A more representative approach to assess the effects from long-term 
exposure to BPs during pregnancy and lactation would be to pre-treat female dams with multiple 
cyclic BP treatments prior to conception. This would in turn achieve a more representative model 
of BP accumulation in maternal bone that can be recycled through maternal bone resorption and 
be a potential risk to fetal and neonatal bone development. 
We only explored one PAM dose representative of a standard clinical dosage that has been used 
during pregnancy to create a snapshot of bone structure prior to changes in bone metabolism that 
are triggered by pregnancy and lactation-induced changes in calcium homeostasis. In addition, we 
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did not want over-saturate the system to induce any toxicity effects. However, exploring a wider 
range of dosages would fully assess the risk/benefit ratio of bone interventions during pregnancy 
and lactation. While studies have explored the effects of toxic dosages of BPs during pregnancy 
and lactation [79-82, 89, 113], better understanding of the risks of BPs can be derived from studies 
identifying the threshold of toxicity during pregnancy and lactation. Furthermore, treatment timing 
will also vary depending on fracture risk diagnosis during pregnancy and lactation to attain the 
best clinical outcome for both mother and offspring. For example, if treatment intervention is 
needed during pregnancy, it might be best to treat with BPs prior to fetal ossification to avoid 
possible BP accumulation in the embryo. On the other hand, if intervention is needed towards the 
end of lactation, a best clinical practice might be to stop lactation since studies have shown post-
lactation bone recovery [132, 133, 202, 203] and our study showed no differences between 
untreated and treated dams by D10 and D15 of lactation.  
It is now well established that BPs have a long half-life and remain embedded in the bone matrix 
until liberated during osteoclastic resorption [18, 69]. Thus, if significant levels of BPs are 
incorporated into the fetal and neonatal skeleton during pregnancy and/or lactation, BP effects 
might not be observed until later stages of rapid growth or adulthood when BPs are revealed 
through bone remodeling. Therefore, although no effects were observed in this study on weaned 
pups, BP exposure risk should not be disregarded and further post-lactation assessment of neonatal 
growth should be considered. In this study, our goal was to analyze the immediate effects in bone 
morphology resulting from potential PAM exposure during skeleton development. However, a 
more direct approach to evaluate the risk of BP exposure during neonatal bone development, as 
well as the role of osteoclasts during early stages of mineralization would be to directly treat 
neonatal mice immediately following birth to contrast direct vs. indirect exposure to the drug.  
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Despite inhibiting lactation-induced maternal bone mass, no effects were observed in fetal and 
neonatal bone development. However, we did not analyze calcium levels in mothers or their 
offspring to verify that PAM did not induce hyper/hypocalcemia. To evaluate if direct disruption 
of maternal calcium homeostasis from PAM-induced anti-resorptive effects prevented offspring 
from receiving the necessary calcium supply, analyzing Ca+ levels in breast milk could help 
address risk of hypocalcemia in neonates. Additionally, evaluating the quality of bone 
mineralization could also help address the difference in calcium content between offspring from 
treated and untreated dams. Due to limited microCT resolution and high porosity in neonatal 
skeleton at day 1, we were only able to quantify BMD, but techniques like scanning electron 
microscope energy dispersive analysis of X-rays (SEM-EDAX) could be used to evaluate the 
differences in elemental composition between neonatal bone surfaces from treated and untreated 
mothers. Furthermore, collecting serum or urine samples from pups to perform analysis on 
osteoclast and osteoblast activity could further assess the indirect impact that BP inhibition of 
maternal bone loss has on neonatal skeleton development.  
Aside from changes in maternal bone metabolism during pregnancy and lactation, several 
hormones like parathyroid hormone related peptide (PTHrP), calcitonin, 1,25 dihydroxy-vitamin 
D, estradiol, prolactin and several others have been shown to play a crucial role in elevating 
intestinal calcium absorption during pregnancy and maintaining calcium homeostasis during 
lactation [158, 204]. However, the mechanisms and role which these hormones play to drive bone 
loss during lactation are only partly understood. Vitamin D has been shown to play a role in 
upregulating maternal calcium absorption, while PTHrP, along with local changes at the bone level 
involving receptor activator of nuclear factor kappa B ligand and osteoprotegerin, have been 
implicated in increasing bone resorption, allowing maternal calcium stores to supply calcium to 
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the fetus [205, 206]. Serum calcitonin levels are increased during pregnancy and potentially play 
a role in protecting the maternal skeleton against excessive resorption during lactation [158]. 
Pregnancy also involves changes in estradiol and prolactin, which are produced by the placenta 
and exhibit an effect on bone metabolism. Studies have shown that estrogen along with PTHrP 
help regulate bone resorption during pregnancy and lactation [207, 208]. Animal studies have 
shown that a surge in prolactin and PTHrP in combination with a decline in estradiol and 
progesterone stimulate lactation events [128, 208, 209]. Thus potential intestinal calcium 
absorption and hormonal changes in the presence of an anti-resorptive like PAM need to be 
addressed to determine which calcium pathway is affected by the anti-resorptive effects of BPs.  
Future Directions 
Before considering translation to humans, the limitations stated above need to be addressed, 
especially when assessing the safety of BP exposure during fetal and neonatal bone development. 
Although we did not observe any differences in body mass, bone morphology and osteoclast 
activity between offspring from untreated and treated dams, results from PAM exposure were 
evaluated at birth and weaned date. However, since our PAM dosage was enough to cross the 
placenta and diffuse into the breast milk, localized BP can still be recycled during rapid growth 
and affect the offspring at later stages in life. Therefore, bone morphology and osteoclast activity 
should be evaluated post-rapid growth or later in adulthood after onset of osteoclastogenesis to 
fully address the effects of BPs. On the maternal side, we can also assess post-lactation effects 
from PAM exposure during pregnancy and lactation. While studies have already shown that 
inhibition of lactation-induced bone loss does not affect bone mass gains post-lactation, we can 
address if a single PAM treatment is enough to retain trabecular structure post-lactation. In 
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addition, running this study in parallel with WT dams will allow us to understand the differences 
in lactation-induced bone loss and bone recovery when an underlying bone disease is present.   
Unlike BPs, anabolic therapies have not shown to have a long-half life, however the effects of 
anabolic therapy during pregnancy and lactation have not been studied. Since SclAb has shown 
promising results in preclinical [41, 44-53] and clinical studies [58, 59], repeating the presented 
study with an anabolic treatment would allow us to further understand bone and calcium 
metabolism during these reproductive periods. More importantly, because SclAb has a large 
molecular weight (24kDa), there is significantly less exposure risk to the offspring. Given that 
pregnancy and lactation induce a significant amount of bone loss, a single intervention with SclAb 
might be enough to recover bone loss if the BP treatment window is missed since this treatment 
window could potentially be expanded with an anabolic therapy. Furthermore, we hypothesize that 
the offspring from this type of study would remain unaffected since maternal calcium homeostasis 
will not be directly affected through anabolic targeting of osteoblast-mediated bone formation 
instead of osteoclast activity. Thus, maternal bone formation might be triggered, ensuring that 
enough calcium is being transferred to the developing fetal and neonatal skeleton. Additionally, it 
would be interesting to see if the same degree of temporal bone loss is expressed with anabolic 
therapy. While in the present study we showed that inhibition of lactation-induced bone loss still 
provided the necessary supply of calcium to the developing offspring and since some studies have 
shown that calcium supplementation does not prevent lactation-induced bone loss [136, 154, 210-
215], it would also be interesting to evaluate if additional bone formation can be triggered with an 
anabolic therapy in combination with a calcium enriched diet to reduce the amount of maternal 
bone loss during lactation.  
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Another important study that can be derived from the present results is to focus entirely in the 
pathways that maintain calcium homeostasis during physiological changes in the maternal 
skeleton. This can be achieved by designing a study that combines both BPs and maternal diet 
(vitamin D and calcium deficiencies) to further understand what pathway drives calcium 
homeostasis during this period of high calcium demand. The main groups in the study will be 
untreated dams in a calcium deficient diet, and BP treated dams in a calcium deficient diet, as it 
would allow us to understand the role intestinal absorption has in calcium homeostasis compared 
to bone resorption.  
 
Low Dose of Bisphosphonate Enhances Sclerostin Antibody-Induced Trabecular Bone 
Mass Gains in Brtl/+ Osteogenesis Imperfecta Mouse Model 
 PAM induced a sclerotic metaphyseal band confirming BPs retention of primary trabeculae 
 Lack of long-term antiresorptive effects were observed in trabecular bone following our 
low dose treatment of PAM monotherapy  
 A significant dose dependent preservation of Tb.N was induced by PAM monotherapy  
 SclAb monotherapy led to gains in both Tb.N and Tb.Th  
 Lack of a saturation response from combination therapy was confirmed since both 
interventions stimulated gains in bone mass through independent means  
 Gains in cortical thickness were attributed to SclAb alone and progressive gains were 
observed following two cycles of SclAb monotherapy 
 Immediate effects of PAM and SclAb led to cumulative gains in trabecular bone mass 
triggered  which were attributed to PAM retention of trabecular number and SclAb-induced 
trabecular thickening  
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 Following two cycles of combination therapy a cumulative increase in bone mass was 
observed in long bones while a synergistic effect was observed in the vertebral body  
 SclAb was the sole contributor of increased stiffness and ultimate load in the femur 
 The whole-bone mechanical properties of the vertebra showed that SclAb contributed to 
improvements in ultimate load while synergistic gains in stiffness were observed after two 
cycles of combination treatment 
Limitations 
This study has several limitations. Because OI is a disease of many mutations, the results of this 
study may not extend to all types of OI. Although the Brtl/+ mouse fragility phenotype is of 
moderate severity, it does not suffer spontaneous fractures. In order to verify that our PAM and 
SclAb combination therapy will be effective in severe cases, we need to assess the effects in 
models like the osteogenesis imperfecta mouse model (oim) strain or Col1a1+/jrt mouse model of 
severe dominant OI. Studies have shown that the oim model has a mutation in the pro-alpha2 chain 
of type I collagen resulting in acute osteopenia, bone deformities and spontaneous fractures [216, 
217]. A more severe model is the Col1a1+/jrt model, which has shown signs of high bone turnover, 
spontaneous fractures, and deformities [218, 219]. Due to their more severe phenotype, these 
models can help confirm the clinical importance of treating severe cases of OI with an 
antiresorptive therapy in combination with an anabolic therapy. 
In many of our outcomes, treatment with our lowest PAM dose alone improved bone mass to WT 
control levels, effectively rescuing the phenotype, while our higher PAM dose induced gains in 
bone mass greater than WT baseline. Although our goal was not to directly titrate our treatment 
outcomes to match untreated WT levels, we believe that further adjustment of treatment doses 
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and/or duration will vary depending on clinical severity to best represent a “rescue” response. 
Furthermore, when dealing with combination treatment studies, the order, timing between 
treatments and doses are highly dependent on the clinical outcome one is trying to achieve.  
Future Directions 
BP mechanism of action when given after closure of the growth plate during skeletal maturity will 
not yield the same findings as observed in this study because turnover of primary spongiosa will 
be nonexistent. In other words, the synergistic benefits observed in this growing model might be 
different in adult mice. However, addressing these effects in an older animal model will be 
beneficial, as cases of severe osteoporosis in post-menopausal women with OI have been reported 
[220]. Furthermore, in an adult model, it may be more beneficial to build bone with an anabolic 
therapy and then preserve it with an anti-resorptive.  
In order to determine the correct number of cycles and timing between cycles for minimum drug 
treatment but equivalent results, a cessation study can be performed to evaluate the long-term 
effects from a single combination cycle. This will allow us to better control the effects of both 
drugs combined in order to avoid a plateau effect. Additionally, understanding the cessation effect 
from PAM and SclAb combination therapy will also help us maintain the treated bone structure to 
WT levels.  
Given the lack of treatment options for patients with severe OI and the lack of knowledge regarding 
the effects of BPs during pregnancy and lactation on both the maternal and fetal/neonatal skeleton; 
this thesis provides valuable insight that will help promote strategic and thought out therapeutic 
interventions for challenging clinical scenarios. Rather than developing new pharmacological 
drugs to achieve a “one treatment fits all” solution, novel approaches to therapeutic can be designed 
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using current and promising antiresorptive and anabolic therapies. By understanding the changes 
in bone metabolism of the clinical conditions under investigation and by combining this knowledge 
with our understanding of the targeted pathways of available and emerging pharmaceuticals, we 
can strategically and systematically optimize bone therapeutics so that the best clinical outcome 
can be achieved.  
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